All Agreements
(Click + to show provisions)
Academic Institution - Company, Research Collaboration Agreement
2016
Academic institution
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[access-to-medicines.equitable-access.redacted-collaboration-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 1220
[provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-2/
[children] =>
)
[business-model.roles-responsibilities.academic-institution-company-research-collaboration-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4090
[provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement/
[children] =>
)
[information-sharing.confidentiality.redacted-collaboration-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 1248
[provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-6/
[children] =>
)
[information-sharing.information-sharing-information-sharing.redacted-collaboration-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 1233
[provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-4/
[children] =>
)
[information-sharing.publication-of-results.redacted-collaboration-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 1233
[provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-4/
[children] =>
)
[information-sharing.technology-transfer.redacted-collaboration-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 1238
[provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-5/
[children] =>
)
[ip-ownership.license-grants.academic-institution-company-research-collaboration-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4092
[provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-3/
[children] =>
)
[ip-ownership.ownership-ip.redacted-collaboration-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 1150
[provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement/
[children] =>
)
[ip-ownership.protection-results.academic-institution-company-research-collaboration-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 4093
[provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-4/
[children] =>
)
[liability.indemnity.academic-institution-company-research-collaboration-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4095
[provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-6/
[children] =>
)
[liability.insurance.academic-institution-company-research-collaboration-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4098
[provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-9/
[children] =>
)
[liability.warranties.academic-institution-company-research-collaboration-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4094
[provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-5/
[children] =>
)
[term-and-termination.effect-of-termination.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 1282
[provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
[children] =>
)
[term-and-termination.term-of-agreement.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 1282
[provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
[children] =>
)
[term-and-termination.termination-and-withdrawal.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 1282
[provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
[children] =>
)
)
Alnylam Pharmaceuticals - University of British Columbia- AlCana Technology, Sponsored Research Agreement
2009
Academic institution
Industry
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 5688
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-5/
[children] =>
)
[access-to-medicines.equitable-access.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 5684
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-4/
[children] =>
)
[business-model.roles-responsibilities.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 5694
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-11/
[children] =>
)
[business-model.royalties-and-payments.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 5693
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-10/
[children] =>
)
[information-sharing.confidentiality.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 5689
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-6/
[children] =>
)
[information-sharing.information-sharing-information-sharing.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 5691
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-8/
[children] =>
)
[information-sharing.publication-of-results.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 5690
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-7/
[children] =>
)
[information-sharing.technology-transfer.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 5692
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-9/
[children] =>
)
[ip-ownership.license-grants.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 5682
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-2/
[children] =>
)
[ip-ownership.ownership-ip.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 5681
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement/
[children] =>
)
[ip-ownership.protection-results.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 5683
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-3/
[children] =>
)
[liability.indemnity.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 5695
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-12/
[children] =>
)
[liability.insurance.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 5696
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-13/
[children] =>
)
[liability.warranties.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 5697
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-14/
[children] =>
)
[term-and-termination.effect-of-termination.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 5700
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-17/
[children] =>
)
[term-and-termination.term-of-agreement.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 5698
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-15/
[children] =>
)
[term-and-termination.termination-and-withdrawal.alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 5699
[provision_permalink] => https://ghiaa.org/provision_document/alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-16/
[children] =>
)
)
AUTM Model Inter-Institutional Research Collaboration Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[business-model.benefit-revenue-sharing.autm-model-inter-institutional-research-collaboration-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 66
[slug] => benefit-revenue-sharing
[title] => Benefit sharing
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Benefit sharing
[provision_id] => 4105
[provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-research-collaboration-agreement/
[children] =>
)
[business-model.royalties-and-payments.autm-model-inter-institutional-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3698
[provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-agreement/
[children] =>
)
[information-sharing.confidentiality.autm-model-iia-5] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 1243
[provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-5/
[children] =>
)
[information-sharing.information-sharing-information-sharing.autm-model-inter-institutional-research-collaboration-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4113
[provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-research-collaboration-agreement-3/
[children] =>
)
[ip-ownership.license-grants.autm-model-iia-3] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1182
[provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-3/
[children] =>
)
[ip-ownership.protection-results.autm-model-iia] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 1164
[provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia/
[children] =>
)
[liability.indemnity.autm-model-iia-6] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1273
[provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-6/
[children] =>
)
[liability.warranties.lambert-agreement-d-9] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 1259
[provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-9/
[children] =>
)
[term-and-termination.effect-of-termination.autm-model-inter-institutional-research-collaboration-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4112
[provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-research-collaboration-agreement-2/
[children] =>
)
[term-and-termination.term-of-agreement.autm-model-iia-7] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 1280
[provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-7/
[children] =>
)
[term-and-termination.termination-and-withdrawal.autm-model-iia-7] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 1280
[provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-7/
[children] =>
)
)
AUTM Preliminary Patent Management Agreement
2013
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[business-model.royalties-and-payments.autm-preliminary-patent-management-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 8458
[provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement-3/
[children] =>
)
[ip-ownership.license-grants.autm-preliminary-patent-management-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 8457
[provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement-2/
[children] =>
)
[ip-ownership.protection-results.autm-preliminary-patent-management-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 8456
[provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement/
[children] =>
)
[liability.indemnity.autm-preliminary-patent-management-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 8460
[provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement-5/
[children] =>
)
[term-and-termination.term-of-agreement.autm-preliminary-patent-management-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 8459
[provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement-4/
[children] =>
)
[term-and-termination.termination-and-withdrawal.autm-preliminary-patent-management-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 8459
[provision_permalink] => https://ghiaa.org/provision_document/autm-preliminary-patent-management-agreement-4/
[children] =>
)
)
AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
2020
Funder
Industry
Diagnostic
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 5775
[provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement/
[children] =>
)
[access-to-medicines.equitable-access.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 5776
[provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-2/
[children] =>
)
[access-to-medicines.pricing.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 5777
[provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-3/
[children] =>
)
[access-to-medicines.territory-access-commitments.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 5778
[provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4/
[children] =>
)
[business-model.supply-purchase-of-products.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 5778
[provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 5779
[provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-5/
[children] =>
)
[ip-ownership.license-grants.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 5775
[provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement/
[children] =>
)
[term-and-termination.term-of-agreement.axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 5781
[provision_permalink] => https://ghiaa.org/provision_document/axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-6/
[children] =>
)
)
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
[access-to-medicines.ensuring-continuity.barda-moderna-covid-19-vaccine-development-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 3758
[provision_permalink] => https://ghiaa.org/provision_document/barda-moderna-covid-19-vaccine-development-agreement-2/
[children] =>
)
[business-model.roles-responsibilities.moderna-barda-contract-for-development-of-mrna-vaccine-5] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 2444
[provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-5/
[children] =>
)
[information-sharing.confidentiality.moderna-barda-contract-for-development-of-mrna-vaccine-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 2443
[provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.barda-moderna-covid-19-vaccine-development-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3764
[provision_permalink] => https://ghiaa.org/provision_document/barda-moderna-covid-19-vaccine-development-agreement-3/
[children] =>
)
[ip-ownership.license-grants.moderna-barda-contract-for-development-of-mrna-vaccine-3] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 2442
[provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-3/
[children] =>
)
[ip-ownership.ownership-ip.moderna-barda-contract-for-development-of-mrna-vaccine-3] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 2442
[provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-3/
[children] =>
)
[ip-ownership.protection-results.moderna-barda-contract-for-development-of-mrna-vaccine-3] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 2442
[provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-3/
[children] =>
)
[liability.indemnity.moderna-barda-contract-for-development-of-mrna-vaccine-2] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 2441
[provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-2/
[children] =>
)
)
BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
2013
Academic institution
Industry
Drug
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.pricing.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 9047
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-3/
[children] =>
)
[access-to-medicines.territory-access-commitments.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 9047
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-3/
[children] =>
)
[business-model.roles-responsibilities.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 9057
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-13/
[children] =>
)
[business-model.royalties-and-payments.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 9050
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-6/
[children] =>
)
[information-sharing.confidentiality.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 9048
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 9049
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-5/
[children] =>
)
[ip-ownership.license-grants.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 9035
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement/
[children] =>
)
[ip-ownership.protection-results.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 9036
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-2/
[children] =>
)
[liability.indemnity.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 9051
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-7/
[children] =>
)
[liability.insurance.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 9052
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-8/
[children] =>
)
[liability.warranties.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 9053
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-9/
[children] =>
)
[term-and-termination.effect-of-termination.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 9055
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-11/
[children] =>
)
[term-and-termination.term-of-agreement.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 9056
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-12/
[children] =>
)
[term-and-termination.termination-and-withdrawal.bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 9054
[provision_permalink] => https://ghiaa.org/provision_document/bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-10/
[children] =>
)
)
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.pricing.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 4214
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3/
[children] =>
)
[business-model.regulatory-strategy.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 4223
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14/
[children] =>
)
[business-model.roles-responsibilities.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4222
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13/
[children] =>
)
[business-model.royalties-and-payments.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 4214
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3/
[children] =>
)
[business-model.supply-purchase-of-products.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 4213
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5/
[children] =>
)
[information-sharing.confidentiality.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4212
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4221
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12/
[children] =>
)
[ip-ownership.license-grants.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4209
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement/
[children] =>
)
[ip-ownership.ownership-ip.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 4209
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement/
[children] =>
)
[ip-ownership.protection-results.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 4210
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2/
[children] =>
)
[liability.indemnity.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4215
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6/
[children] =>
)
[liability.insurance.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4216
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7/
[children] =>
)
[liability.warranties.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4217
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8/
[children] =>
)
[term-and-termination.effect-of-termination.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4220
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11/
[children] =>
)
[term-and-termination.term-of-agreement.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4218
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9/
[children] =>
)
[term-and-termination.termination-and-withdrawal.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4219
[provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10/
[children] =>
)
)
Boston University Startup Exclusive License Template
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[access-to-medicines.equitable-access.boston-university-startup-exclusive-license-template] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 4858
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template/
[children] =>
)
[access-to-medicines.territory-access-commitments.boston-university-startup-exclusive-license-template-6] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 4863
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-6/
[children] =>
)
[business-model.roles-responsibilities.boston-university-startup-exclusive-license-template-11] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4868
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-11/
[children] =>
)
[business-model.royalties-and-payments.boston-university-startup-exclusive-license-template-7] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 4864
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-7/
[children] =>
)
[information-sharing.confidentiality.boston-university-startup-exclusive-license-template-12] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4869
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-12/
[children] =>
)
[information-sharing.information-sharing-information-sharing.boston-university-startup-exclusive-license-template-4] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4861
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-4/
[children] =>
)
[ip-ownership.license-grants.bu-startup-exclusive-license] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1127
[provision_permalink] => https://ghiaa.org/provision_document/bu-startup-exclusive-license/
[children] =>
)
[ip-ownership.protection-results.boston-university-startup-exclusive-license-template-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 4859
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-2/
[children] =>
)
[liability.indemnity.bu-startup-exclusive-license-2] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1272
[provision_permalink] => https://ghiaa.org/provision_document/bu-startup-exclusive-license-2/
[children] =>
)
[liability.insurance.boston-university-startup-exclusive-license-template-8] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4865
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-8/
[children] =>
)
[liability.warranties.boston-university-startup-exclusive-license-template-3] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4860
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-3/
[children] =>
)
[term-and-termination.effect-of-termination.boston-university-startup-exclusive-license-template-10] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4867
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-10/
[children] =>
)
[term-and-termination.term-of-agreement.boston-university-startup-exclusive-license-template-9] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4866
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-9/
[children] =>
)
[term-and-termination.termination-and-withdrawal.boston-university-startup-exclusive-license-template-5] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4862
[provision_permalink] => https://ghiaa.org/provision_document/boston-university-startup-exclusive-license-template-5/
[children] =>
)
)
CARB-X Research Subaward Agreement
2019
Academic institution
Funder
Industry
Drug
Preclinical
Early clinical (through Phase 2)
Array
(
[access-to-medicines.ensuring-continuity.carb-x-research-subaward-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 1187
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-2/
[children] =>
)
[access-to-medicines.equitable-access.carb-x-research-subaward-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 4516
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement/
[children] =>
)
[access-to-medicines.territory-access-commitments.carb-x-research-subaward-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 5622
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-4/
[children] =>
)
[business-model.regulatory-strategy.carb-x-research-subaward-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 5625
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-14/
[children] =>
)
[business-model.roles-responsibilities.carb-x-research-subaward-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 5624
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-6/
[children] =>
)
[business-model.royalties-and-payments.carb-x-research-subaward-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 5626
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-7/
[children] =>
)
[information-sharing.confidentiality.carb-x-research-subaward-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 5627
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-8/
[children] =>
)
[information-sharing.information-sharing-information-sharing.carb-x-research-subaward-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 5623
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-5/
[children] =>
)
[information-sharing.publication-of-results.carb-x-research-subaward-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 1218
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-3/
[children] =>
)
[ip-ownership.ownership-ip.carb-x-research-subaward-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 5632
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-11/
[children] =>
)
[liability.indemnity.carb-x-research-subaward-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 5633
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-12/
[children] =>
)
[liability.insurance.carb-x-research-subaward-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 5634
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-13/
[children] =>
)
[liability.warranties.carb-x-research-subaward-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 5631
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-10/
[children] =>
)
[term-and-termination.effect-of-termination.carb-x-research-subaward-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 5629
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-9/
[children] =>
)
[term-and-termination.termination-and-withdrawal.carb-x-research-subaward-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 5629
[provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-9/
[children] =>
)
)
CAVD Data & Materials Sharing Agreement
2006
Academic institution
Funder
Government
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[information-sharing.confidentiality.gates-foundation-data-materials-sharing-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 1254
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-data-materials-sharing-agreement-4/
[children] =>
)
[ip-ownership.license-grants.cavd-data-materials-sharing-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1134
[provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-2/
[children] =>
)
[ip-ownership.ownership-ip.cavd-data-materials-sharing-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 1134
[provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-2/
[children] =>
)
)
Cellscript - BioNTech mRNA Technology Patent Sublicense
2016
Industry
Vaccine
Preclinical
Array
(
[business-model.roles-responsibilities.cellscript-biontech-mrna-technology-patent-sublicense-11] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4490
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-11/
[children] =>
)
[business-model.royalties-and-payments.cellscript-biontech-mrna-technology-patent-sublicense-4] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 4483
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-4/
[children] =>
)
[information-sharing.confidentiality.cellscript-biontech-mrna-technology-patent-sublicense-3] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4482
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-3/
[children] =>
)
[information-sharing.information-sharing-information-sharing.cellscript-biontech-mrna-technology-patent-sublicense-10] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4489
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-10/
[children] =>
)
[ip-ownership.license-grants.cellscript-biontech-mrna-technology-patent-sublicense] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4469
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense/
[children] =>
)
[ip-ownership.protection-results.cellscript-biontech-mrna-technology-patent-sublicense-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 4481
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-2/
[children] =>
)
[liability.indemnity.cellscript-biontech-mrna-technology-patent-sublicense-5] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4484
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-5/
[children] =>
)
[liability.insurance.cellscript-biontech-mrna-technology-patent-sublicense-12] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4491
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-12/
[children] =>
)
[liability.warranties.cellscript-biontech-mrna-technology-patent-sublicense-6] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4485
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-6/
[children] =>
)
[term-and-termination.effect-of-termination.cellscript-biontech-mrna-technology-patent-sublicense-9] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4488
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-9/
[children] =>
)
[term-and-termination.term-of-agreement.cellscript-biontech-mrna-technology-patent-sublicense-7] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4486
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-7/
[children] =>
)
[term-and-termination.termination-and-withdrawal.cellscript-biontech-mrna-technology-patent-sublicense-8] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4487
[provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-8/
[children] =>
)
)
CEPI - CureVac, Framework Partnering Agreement
2019
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.cepi-curevac-framework-partnering-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 3329
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-11/
[children] =>
)
[access-to-medicines.equitable-access.cepi-curevac-framework-partnering-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 8461
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-7/
[children] =>
)
[access-to-medicines.outbreak-preparedness.cepi-curevac-framework-partnering-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 102
[slug] => outbreak-preparedness
[title] => Preparedness & response
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Preparedness & response
[provision_id] => 3327
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-9/
[children] =>
)
[access-to-medicines.pricing.cepi-curevac-framework-partnering-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 5427
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-5/
[children] =>
)
[access-to-medicines.territory-access-commitments.cepi-curevac-framework-partnering-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 4580
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-3/
[children] =>
)
[business-model.benefit-revenue-sharing.cepi-curevac-framework-partnering-agreement-13-2] => GHIAA2019\IssueItem Object
(
[ID] => 66
[slug] => benefit-revenue-sharing
[title] => Benefit sharing
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Benefit sharing
[provision_id] => 3321
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-13-2/
[children] =>
)
[business-model.regulatory-strategy.cepi-curevac-framework-partnering-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 3318
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-4/
[children] =>
)
[business-model.roles-responsibilities.cepi-curevac-framework-partnering-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3323
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-6/
[children] =>
)
[business-model.royalties-and-payments.cepi-curevac-framework-partnering-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3315
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement/
[children] =>
)
[information-sharing.confidentiality.cepi-curevac-framework-partnering-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3338
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-16/
[children] =>
)
[information-sharing.information-sharing-information-sharing.cepi-curevac-framework-partnering-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3316
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-2/
[children] =>
)
[information-sharing.publication-of-results.cepi-curevac-framework-partnering-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 3326
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-8/
[children] =>
)
[information-sharing.technology-transfer.cepi-curevac-framework-partnering-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 4580
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-3/
[children] =>
)
[ip-ownership.license-grants.cepi-curevac-framework-partnering-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3329
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-11/
[children] =>
)
[ip-ownership.ownership-ip.cepi-curevac-framework-partnering-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3331
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-13/
[children] =>
)
[ip-ownership.protection-results.cepi-curevac-framework-partnering-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 3336
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-14/
[children] =>
)
[liability.indemnity.cepi-curevac-framework-partnering-agreement-19] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3341
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-19/
[children] =>
)
[liability.insurance.cepi-curevac-framework-partnering-agreement-20] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 3342
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-20/
[children] =>
)
[liability.warranties.cepi-curevac-framework-partnering-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3339
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-17/
[children] =>
)
[term-and-termination.effect-of-termination.cepi-curevac-framework-partnering-agreement-22] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 3344
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-22/
[children] =>
)
[term-and-termination.term-of-agreement.cepi-curevac-framework-partnering-agreement-21] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3343
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-21/
[children] =>
)
[term-and-termination.termination-and-withdrawal.cepi-curevac-framework-partnering-agreement-21] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 3343
[provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-21/
[children] =>
)
)
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.equitable-access.cepi-dynavax-covid-19-material-reservation-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 4128
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement/
[children] =>
)
[access-to-medicines.pricing.cepi-dynavax-covid-19-material-reservation-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 4129
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-2/
[children] =>
)
[access-to-medicines.territory-access-commitments.cepi-dynavax-covid-19-material-reservation-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 4129
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-2/
[children] =>
)
[business-model.regulatory-strategy.cepi-dynavax-covid-19-material-reservation-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 4141
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-13/
[children] =>
)
[business-model.roles-responsibilities.cepi-dynavax-covid-19-material-reservation-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4140
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-12/
[children] =>
)
[business-model.royalties-and-payments.cepi-dynavax-covid-19-material-reservation-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 4133
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-5/
[children] =>
)
[business-model.supply-purchase-of-products.cepi-dynavax-covid-19-material-reservation-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 4131
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-4/
[children] =>
)
[information-sharing.confidentiality.cepi-dynavax-covid-19-material-reservation-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4130
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-3/
[children] =>
)
[information-sharing.information-sharing-information-sharing.cepi-dynavax-covid-19-material-reservation-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4139
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-11/
[children] =>
)
[liability.indemnity.cepi-dynavax-covid-19-material-reservation-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4134
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-6/
[children] =>
)
[liability.warranties.cepi-dynavax-covid-19-material-reservation-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4135
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-7/
[children] =>
)
[term-and-termination.effect-of-termination.cepi-dynavax-covid-19-material-reservation-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4138
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-10/
[children] =>
)
[term-and-termination.term-of-agreement.cepi-dynavax-covid-19-material-reservation-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4136
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-8/
[children] =>
)
[term-and-termination.termination-and-withdrawal.cepi-dynavax-covid-19-material-reservation-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4137
[provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-9/
[children] =>
)
)
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Vaccine
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 2890
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5/
[children] =>
)
[access-to-medicines.equitable-access.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 2892
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6/
[children] =>
)
[access-to-medicines.outbreak-preparedness.cepi-novavax-covid-19-vaccine-funding-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 102
[slug] => outbreak-preparedness
[title] => Preparedness & response
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Preparedness & response
[provision_id] => 5782
[provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-8/
[children] =>
)
[access-to-medicines.pricing.cepi-novavax-covid-19-vaccine-funding-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 5652
[provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-6/
[children] =>
)
[access-to-medicines.territory-access-commitments.cepi-novavax-covid-19-vaccine-funding-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 8462
[provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-9/
[children] =>
)
[business-model.benefit-revenue-sharing.cepi-novavax-covid-19-vaccine-funding-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 66
[slug] => benefit-revenue-sharing
[title] => Benefit sharing
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Benefit sharing
[provision_id] => 4204
[provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-4/
[children] =>
)
[business-model.regulatory-strategy.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 2889
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4/
[children] =>
)
[business-model.roles-responsibilities.cepi-novavax-covid-19-vaccine-funding-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4200
[provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-2/
[children] =>
)
[business-model.royalties-and-payments.cepi-novavax-covid-19-vaccine-funding-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3493
[provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement/
[children] =>
)
[business-model.supply-purchase-of-products.cepi-novavax-covid-19-vaccine-funding-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 5653
[provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-7/
[children] =>
)
[information-sharing.confidentiality.cepi-novavax-covid-19-vaccine-funding-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4205
[provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-5/
[children] =>
)
[information-sharing.information-sharing-information-sharing.cepi-novavax-covid-19-vaccine-funding-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4201
[provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-3/
[children] =>
)
[information-sharing.publication-of-results.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 2893
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7/
[children] =>
)
[ip-ownership.license-grants.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 2890
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5/
[children] =>
)
[ip-ownership.ownership-ip.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 2885
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement/
[children] =>
)
[ip-ownership.protection-results.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 2885
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement/
[children] =>
)
[liability.indemnity.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 2908
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9/
[children] =>
)
[liability.insurance.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 2908
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9/
[children] =>
)
[liability.warranties.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 2907
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8/
[children] =>
)
[term-and-termination.effect-of-termination.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 2909
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
[children] =>
)
[term-and-termination.term-of-agreement.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 2909
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
[children] =>
)
[term-and-termination.termination-and-withdrawal.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 2909
[provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
[children] =>
)
)
CEPI - Valneva, Chikungunya Vaccine Funding Agreement
2019
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
[access-to-medicines.ensuring-continuity.cepi-valneva-chikungunya-vaccine-funding-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 3748
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-10/
[children] =>
)
[access-to-medicines.equitable-access.cepi-valneva-chikungunya-vaccine-funding-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 8467
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-2/
[children] =>
)
[access-to-medicines.outbreak-preparedness.cepi-valneva-chikungunya-vaccine-funding-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 102
[slug] => outbreak-preparedness
[title] => Preparedness & response
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Preparedness & response
[provision_id] => 3724
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-3/
[children] =>
)
[access-to-medicines.pricing.cepi-valneva-chikungunya-vaccine-funding-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 8468
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-13/
[children] =>
)
[access-to-medicines.territory-access-commitments.cepi-valneva-chikungunya-vaccine-funding-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 3726
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-5/
[children] =>
)
[business-model.benefit-revenue-sharing.cepi-valneva-chikungunya-vaccine-funding-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 66
[slug] => benefit-revenue-sharing
[title] => Benefit sharing
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Benefit sharing
[provision_id] => 3747
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-9/
[children] =>
)
[business-model.regulatory-strategy.cepi-valneva-chikungunya-vaccine-funding-agreement-20] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 8484
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-20/
[children] =>
)
[business-model.roles-responsibilities.cepi-valneva-chikungunya-vaccine-funding-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3756
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-17/
[children] =>
)
[business-model.royalties-and-payments.cepi-valneva-chikungunya-vaccine-funding-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3722
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement/
[children] =>
)
[information-sharing.confidentiality.cepi-valneva-chikungunya-vaccine-funding-agreement-18] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3757
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-18/
[children] =>
)
[information-sharing.information-sharing-information-sharing.cepi-valneva-chikungunya-vaccine-funding-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3725
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-4/
[children] =>
)
[information-sharing.publication-of-results.cepi-valneva-chikungunya-vaccine-funding-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 3744
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-7/
[children] =>
)
[information-sharing.technology-transfer.cepi-valneva-chikungunya-vaccine-funding-agreement-19] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 8469
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-19/
[children] =>
)
[ip-ownership.license-grants.cepi-valneva-chikungunya-vaccine-funding-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3748
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-10/
[children] =>
)
[ip-ownership.ownership-ip.cepi-valneva-chikungunya-vaccine-funding-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3743
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-6/
[children] =>
)
[ip-ownership.protection-results.cepi-valneva-chikungunya-vaccine-funding-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 3746
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-8/
[children] =>
)
[liability.indemnity.cepi-valneva-chikungunya-vaccine-funding-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3751
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-12/
[children] =>
)
[liability.insurance.cepi-valneva-chikungunya-vaccine-funding-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 3753
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-14/
[children] =>
)
[liability.warranties.cepi-valneva-chikungunya-vaccine-funding-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3749
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-11/
[children] =>
)
[term-and-termination.effect-of-termination.cepi-valneva-chikungunya-vaccine-funding-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 3755
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-16/
[children] =>
)
[term-and-termination.term-of-agreement.cepi-valneva-chikungunya-vaccine-funding-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3754
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-15/
[children] =>
)
[term-and-termination.termination-and-withdrawal.cepi-valneva-chikungunya-vaccine-funding-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 3754
[provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-15/
[children] =>
)
)
CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
2021
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
[access-to-medicines.ensuring-continuity.cepi-vbi-covid-19-vaccine-development-funding-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 8151
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-8/
[children] =>
)
[access-to-medicines.equitable-access.cepi-vbi-covid-19-vaccine-development-funding-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 8051
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement/
[children] =>
)
[access-to-medicines.outbreak-preparedness.cepi-vbi-covid-19-vaccine-development-funding-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 102
[slug] => outbreak-preparedness
[title] => Preparedness & response
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Preparedness & response
[provision_id] => 8130
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-3/
[children] =>
)
[access-to-medicines.pricing.cepi-vbi-covid-19-vaccine-development-funding-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 8129
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-2/
[children] =>
)
[access-to-medicines.territory-access-commitments.cepi-vbi-covid-19-vaccine-development-funding-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 8131
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-4/
[children] =>
)
[business-model.benefit-revenue-sharing.cepi-vbi-covid-19-vaccine-development-funding-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 66
[slug] => benefit-revenue-sharing
[title] => Benefit sharing
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Benefit sharing
[provision_id] => 8190
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-11/
[children] =>
)
[business-model.regulatory-strategy.cepi-vbi-covid-19-vaccine-development-funding-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 8192
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-13/
[children] =>
)
[business-model.roles-responsibilities.cepi-vbi-covid-19-vaccine-development-funding-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 8143
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-6/
[children] =>
)
[business-model.royalties-and-payments.cepi-vbi-covid-19-vaccine-development-funding-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 8191
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-12/
[children] =>
)
[business-model.supply-purchase-of-products.cepi-vbi-covid-19-vaccine-development-funding-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 8131
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-4/
[children] =>
)
[information-sharing.confidentiality.cepi-vbi-covid-19-vaccine-development-funding-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 8152
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-9/
[children] =>
)
[information-sharing.information-sharing-information-sharing.cepi-vbi-covid-19-vaccine-development-funding-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 8142
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-5/
[children] =>
)
[information-sharing.publication-of-results.cepi-vbi-covid-19-vaccine-development-funding-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 8157
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-10/
[children] =>
)
[ip-ownership.license-grants.cepi-vbi-covid-19-vaccine-development-funding-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 8150
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-7/
[children] =>
)
[ip-ownership.ownership-ip.cepi-vbi-covid-19-vaccine-development-funding-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 8150
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-7/
[children] =>
)
[ip-ownership.protection-results.cepi-vbi-covid-19-vaccine-development-funding-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 8150
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-7/
[children] =>
)
[liability.indemnity.cepi-vbi-covid-19-vaccine-development-funding-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 8311
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-14/
[children] =>
)
[liability.insurance.cepi-vbi-covid-19-vaccine-development-funding-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 8311
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-14/
[children] =>
)
[liability.warranties.cepi-vbi-covid-19-vaccine-development-funding-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 8312
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-15/
[children] =>
)
[term-and-termination.effect-of-termination.cepi-vbi-covid-19-vaccine-development-funding-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 8314
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-17/
[children] =>
)
[term-and-termination.term-of-agreement.cepi-vbi-covid-19-vaccine-development-funding-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 8313
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-16/
[children] =>
)
[term-and-termination.termination-and-withdrawal.cepi-vbi-covid-19-vaccine-development-funding-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 8314
[provision_permalink] => https://ghiaa.org/provision_document/cepi-vbi-covid-19-vaccine-development-funding-agreement-17/
[children] =>
)
)
CEPI CfP3i Vaccine Funding Agreement Template
2018
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
[access-to-medicines.ensuring-continuity.cepi-cfp3i-template-funding-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 1205
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-4/
[children] =>
)
[access-to-medicines.equitable-access.cepi-cfp3i-template-funding-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 1202
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-6/
[children] =>
)
[access-to-medicines.outbreak-preparedness.cepi-cfp3i-template-funding-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 102
[slug] => outbreak-preparedness
[title] => Preparedness & response
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Preparedness & response
[provision_id] => 1204
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-5/
[children] =>
)
[access-to-medicines.territory-access-commitments.cepi-cfp3i-template-funding-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 8480
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-9/
[children] =>
)
[business-model.benefit-revenue-sharing.cepi-cfp3i-template-funding-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 66
[slug] => benefit-revenue-sharing
[title] => Benefit sharing
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Benefit sharing
[provision_id] => 1203
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-3/
[children] =>
)
[business-model.regulatory-strategy.cepi-cfp3i-template-funding-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 8482
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-11/
[children] =>
)
[business-model.roles-responsibilities.cepi-cfp3i-template-funding-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 8479
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-2/
[children] =>
)
[business-model.royalties-and-payments.cepi-cfp3i-template-funding-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 8481
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-10/
[children] =>
)
[information-sharing.confidentiality.cepi-cfp3i-vaccine-funding-agreement-template] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 8491
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-vaccine-funding-agreement-template/
[children] =>
)
[information-sharing.information-sharing-information-sharing.cepi-cfp3i-template-funding-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3736
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement/
[children] =>
)
[information-sharing.publication-of-results.cepi-cfpi3-template-funding-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 1221
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfpi3-template-funding-agreement/
[children] =>
)
[information-sharing.technology-transfer.cepi-cfp3i-template-funding-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 8485
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-12/
[children] =>
)
[ip-ownership.license-grants.cepi-cfp3i-template-funding-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1205
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-4/
[children] =>
)
[ip-ownership.ownership-ip.cepi-cfp3i-template-funding-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 1159
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-7/
[children] =>
)
[ip-ownership.protection-results.cepi-cfp3i-template-funding-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 996
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-8/
[children] =>
)
[liability.indemnity.cepi-cfp3i-template-funding-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 8487
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-14/
[children] =>
)
[liability.insurance.cepi-cfp3i-template-funding-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 8488
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-15/
[children] =>
)
[liability.warranties.cepi-cfp3i-template-funding-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 8486
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-13/
[children] =>
)
[term-and-termination.effect-of-termination.cepi-cfp3i-template-funding-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 8490
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-17/
[children] =>
)
[term-and-termination.term-of-agreement.cepi-cfp3i-template-funding-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 8489
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-16/
[children] =>
)
[term-and-termination.termination-and-withdrawal.cepi-cfp3i-template-funding-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 8489
[provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-16/
[children] =>
)
)
CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
2021
Government
Multilateral organization
Diagnostic
Commercialization
Array
(
[access-to-medicines.pricing.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 4796
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement/
[children] =>
)
[business-model.roles-responsibilities.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4806
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9/
[children] =>
)
[business-model.royalties-and-payments.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 4798
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3/
[children] =>
)
[information-sharing.confidentiality.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4800
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4808
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11/
[children] =>
)
[information-sharing.technology-transfer.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 4801
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5/
[children] =>
)
[ip-ownership.license-grants.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4796
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement/
[children] =>
)
[ip-ownership.protection-results.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 4797
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2/
[children] =>
)
[liability.warranties.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4802
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6/
[children] =>
)
[term-and-termination.effect-of-termination.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4807
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10/
[children] =>
)
[term-and-termination.term-of-agreement.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4804
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7/
[children] =>
)
[term-and-termination.termination-and-withdrawal.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4805
[provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8/
[children] =>
)
)
CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
2021
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[business-model.regulatory-strategy.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 4002
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3/
[children] =>
)
[business-model.roles-responsibilities.curevac-and-gsk-collaboration-and-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4009
[provision_permalink] => https://ghiaa.org/provision_document/curevac-and-gsk-collaboration-and-license-agreement-2/
[children] =>
)
[business-model.royalties-and-payments.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 4004
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5/
[children] =>
)
[business-model.supply-purchase-of-products.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 4007
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8/
[children] =>
)
[information-sharing.confidentiality.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4013
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12/
[children] =>
)
[information-sharing.information-sharing-information-sharing.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4003
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4/
[children] =>
)
[information-sharing.publication-of-results.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 4014
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13/
[children] =>
)
[information-sharing.technology-transfer.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 4006
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7/
[children] =>
)
[ip-ownership.license-grants.curevac-and-gsk-collaboration-and-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3819
[provision_permalink] => https://ghiaa.org/provision_document/curevac-and-gsk-collaboration-and-license-agreement/
[children] =>
)
[ip-ownership.license-grants.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4001
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2/
[children] =>
)
[ip-ownership.ownership-ip.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 4011
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10/
[children] =>
)
[ip-ownership.protection-results.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 3997
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement/
[children] =>
)
[liability.indemnity.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4016
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15/
[children] =>
)
[liability.insurance.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4024
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22/
[children] =>
)
[liability.warranties.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4017
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16/
[children] =>
)
[term-and-termination.effect-of-termination.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4022
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20/
[children] =>
)
[term-and-termination.term-of-agreement.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4020
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18/
[children] =>
)
[term-and-termination.termination-and-withdrawal.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4021
[provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19/
[children] =>
)
)
Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
[business-model.regulatory-strategy.pfizer-biontech-dominican-republic-binding-term-sheet-2] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 3120
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-2/
[children] =>
)
[business-model.roles-responsibilities.pfizer-biontech-dominican-republic-binding-term-sheet-7] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3125
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-7/
[children] =>
)
[business-model.supply-purchase-of-products.pfizer-biontech-dominican-republic-binding-term-sheet-3] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3121
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-3/
[children] =>
)
[information-sharing.confidentiality.pfizer-biontech-dominican-republic-binding-term-sheet-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3122
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.pfizer-biontech-dominican-republic-binding-term-sheet-9] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3127
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-9/
[children] =>
)
[ip-ownership.ownership-ip.pfizer-biontech-dominican-republic-binding-term-sheet] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3119
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet/
[children] =>
)
[liability.indemnity.pfizer-biontech-dominican-republic-binding-term-sheet-5] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3123
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-5/
[children] =>
)
[liability.warranties.pfizer-biontech-dominican-republic-binding-term-sheet-5] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3123
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-5/
[children] =>
)
[liability.warranties.pfizer-biontech-dominican-republic-binding-term-sheet-6] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3124
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-6/
[children] =>
)
[term-and-termination.term-of-agreement.pfizer-biontech-dominican-republic-binding-term-sheet-8] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3126
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-8/
[children] =>
)
)
Drugs For Neglected Diseases Initiative - BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
2009
Industry
Product development partnership
Drug
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.territory-access-commitments.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 6317
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-4/
[children] =>
)
[business-model.regulatory-strategy.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 6326
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-11/
[children] =>
)
[business-model.roles-responsibilities.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 6325
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-10/
[children] =>
)
[business-model.royalties-and-payments.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 6324
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-9/
[children] =>
)
[business-model.supply-purchase-of-products.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 6323
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-8/
[children] =>
)
[information-sharing.confidentiality.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 6318
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-5/
[children] =>
)
[information-sharing.information-sharing-information-sharing.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 6322
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-7/
[children] =>
)
[information-sharing.publication-of-results.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 6319
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-6/
[children] =>
)
[information-sharing.technology-transfer.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 6322
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-7/
[children] =>
)
[ip-ownership.license-grants.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 6316
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-3/
[children] =>
)
[ip-ownership.ownership-ip.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 6314
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement/
[children] =>
)
[ip-ownership.protection-results.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 6315
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-2/
[children] =>
)
[liability.indemnity.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 6327
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-12/
[children] =>
)
[liability.insurance.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 6328
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-13/
[children] =>
)
[liability.warranties.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 6329
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-14/
[children] =>
)
[term-and-termination.effect-of-termination.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 6333
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-17/
[children] =>
)
[term-and-termination.term-of-agreement.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 6330
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-15/
[children] =>
)
[term-and-termination.termination-and-withdrawal.drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 6332
[provision_permalink] => https://ghiaa.org/provision_document/drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-16/
[children] =>
)
)
Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
2021
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 4838
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5/
[children] =>
)
[access-to-medicines.pricing.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 4840
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-6/
[children] =>
)
[access-to-medicines.territory-access-commitments.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 4840
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-6/
[children] =>
)
[business-model.roles-responsibilities.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4850
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-16/
[children] =>
)
[business-model.royalties-and-payments.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 4842
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-8/
[children] =>
)
[information-sharing.confidentiality.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4841
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-7/
[children] =>
)
[information-sharing.information-sharing-information-sharing.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4849
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-15/
[children] =>
)
[ip-ownership.license-grants.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4835
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-2/
[children] =>
)
[ip-ownership.ownership-ip.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 4834
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement/
[children] =>
)
[ip-ownership.protection-results.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 4837
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-4/
[children] =>
)
[liability.indemnity.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4843
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-9/
[children] =>
)
[liability.insurance.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4844
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-10/
[children] =>
)
[liability.warranties.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4845
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-11/
[children] =>
)
[term-and-termination.effect-of-termination.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4848
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-14/
[children] =>
)
[term-and-termination.term-of-agreement.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4846
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-12/
[children] =>
)
[term-and-termination.termination-and-withdrawal.elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4847
[provision_permalink] => https://ghiaa.org/provision_document/elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-13/
[children] =>
)
)
Entasis - DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
2017
Industry
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.equitable-access.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 4877
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-3/
[children] =>
)
[access-to-medicines.pricing.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 4877
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-3/
[children] =>
)
[business-model.benefit-revenue-sharing.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 66
[slug] => benefit-revenue-sharing
[title] => Benefit sharing
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Benefit sharing
[provision_id] => 4894
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-17/
[children] =>
)
[business-model.regulatory-strategy.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 4893
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-16/
[children] =>
)
[business-model.roles-responsibilities.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4892
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-15/
[children] =>
)
[business-model.supply-purchase-of-products.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 4884
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-8/
[children] =>
)
[information-sharing.confidentiality.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4878
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4882
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-6/
[children] =>
)
[information-sharing.publication-of-results.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 4881
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-5/
[children] =>
)
[information-sharing.technology-transfer.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 4883
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-7/
[children] =>
)
[ip-ownership.license-grants.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4875
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement/
[children] =>
)
[ip-ownership.ownership-ip.entasis-dndi-gardp-gonorrhea-medication-collaboration-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 4873
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhea-medication-collaboration-agreement/
[children] =>
)
[ip-ownership.protection-results.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 4876
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-2/
[children] =>
)
[liability.indemnity.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4885
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-9/
[children] =>
)
[liability.insurance.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4886
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-10/
[children] =>
)
[liability.warranties.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4888
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-11/
[children] =>
)
[term-and-termination.effect-of-termination.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4891
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-14/
[children] =>
)
[term-and-termination.term-of-agreement.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4889
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-12/
[children] =>
)
[term-and-termination.termination-and-withdrawal.entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4890
[provision_permalink] => https://ghiaa.org/provision_document/entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-13/
[children] =>
)
)
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.donation.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 271
[slug] => donation
[title] => Donation
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Donation
[provision_id] => 2540
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11/
[children] =>
)
[access-to-medicines.ensuring-continuity.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 2544
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8/
[children] =>
)
[business-model.regulatory-strategy.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 2541
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10/
[children] =>
)
[business-model.roles-responsibilities.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 2545
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7/
[children] =>
)
[business-model.royalties-and-payments.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 2543
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12/
[children] =>
)
[business-model.supply-purchase-of-products.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 2540
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11/
[children] =>
)
[information-sharing.confidentiality.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 2549
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3/
[children] =>
)
[information-sharing.information-sharing-information-sharing.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 2541
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10/
[children] =>
)
[ip-ownership.license-grants.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 2544
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8/
[children] =>
)
[ip-ownership.ownership-ip.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 2544
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8/
[children] =>
)
[liability.indemnity.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 2547
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5/
[children] =>
)
[liability.warranties.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 2542
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9/
[children] =>
)
[term-and-termination.effect-of-termination.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 2553
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2/
[children] =>
)
[term-and-termination.term-of-agreement.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 2553
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2/
[children] =>
)
[term-and-termination.termination-and-withdrawal.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 2553
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2/
[children] =>
)
)
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.donation.curevac-ec-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 271
[slug] => donation
[title] => Donation
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Donation
[provision_id] => 2471
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement/
[children] =>
)
[access-to-medicines.outbreak-preparedness.curevac-ec-covid-19-vaccine-advance-purchase-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 102
[slug] => outbreak-preparedness
[title] => Preparedness & response
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Preparedness & response
[provision_id] => 2470
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-14/
[children] =>
)
[business-model.regulatory-strategy.curevac-ec-covid-19-vaccine-advance-purchase-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 2473
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-12/
[children] =>
)
[business-model.roles-responsibilities.curevac-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 2477
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-8/
[children] =>
)
[business-model.royalties-and-payments.curevac-ec-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 2475
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-10/
[children] =>
)
[business-model.supply-purchase-of-products.curevac-ec-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 2471
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement/
[children] =>
)
[information-sharing.confidentiality.curevac-ec-covid-19-vaccine-advance-purchase-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 2481
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.european-commission-curevac-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3741
[provision_permalink] => https://ghiaa.org/provision_document/european-commission-curevac-covid-19-vaccine-advance-purchase-agreement/
[children] =>
)
[ip-ownership.license-grants.curevac-ec-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 2476
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-9/
[children] =>
)
[ip-ownership.ownership-ip.curevac-ec-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 2476
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-9/
[children] =>
)
[liability.indemnity.curevac-ec-covid-19-vaccine-advance-purchase-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 2479
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-6/
[children] =>
)
[liability.warranties.curevac-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 2474
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-11/
[children] =>
)
[term-and-termination.effect-of-termination.european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4058
[provision_permalink] => https://ghiaa.org/provision_document/european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2/
[children] =>
)
[term-and-termination.termination-and-withdrawal.curevac-ec-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 2482
[provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-3/
[children] =>
)
)
FIND Sample Funding Terms and Conditions
2021
Academic institution
Industry
Product development partnership
Diagnostic
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.equitable-access.find-sample-funding-terms-and-conditions] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 7562
[provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions/
[children] =>
)
[access-to-medicines.pricing.find-sample-funding-terms-and-conditions-2] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 7563
[provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-2/
[children] =>
)
[access-to-medicines.territory-access-commitments.find-sample-funding-terms-and-conditions-3] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 7567
[provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-3/
[children] =>
)
[business-model.regulatory-strategy.find-sample-funding-terms-and-conditions-7] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 7580
[provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-7/
[children] =>
)
[business-model.roles-responsibilities.find-sample-funding-terms-and-conditions-6] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 7570
[provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-6/
[children] =>
)
[information-sharing.publication-of-results.find-sample-funding-terms-and-conditions-4] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 7568
[provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-4/
[children] =>
)
[information-sharing.technology-transfer.find-sample-funding-terms-and-conditions-5] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 7569
[provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-5/
[children] =>
)
[ip-ownership.license-grants.find-sample-funding-terms-and-conditions-5] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 7569
[provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-5/
[children] =>
)
[liability.indemnity.find-sample-funding-terms-and-conditions-8] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 7581
[provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-8/
[children] =>
)
[liability.warranties.find-sample-funding-terms-and-conditions-9] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 7582
[provision_permalink] => https://ghiaa.org/provision_document/find-sample-funding-terms-and-conditions-9/
[children] =>
)
)
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.territory-access-commitments.fiocruz-astrazeneca-covid-19-technological-order-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 3420
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement/
[children] =>
)
[business-model.regulatory-strategy.fiocruz-astrazeneca-covid-19-technological-order-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 3424
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-4/
[children] =>
)
[business-model.roles-responsibilities.fiocruz-astrazeneca-covid-19-technological-order-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3427
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-6/
[children] =>
)
[business-model.royalties-and-payments.fiocruz-astrazeneca-covid-19-technological-order-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3433
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-10/
[children] =>
)
[information-sharing.confidentiality.fiocruz-astrazeneca-covid-19-technological-order-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3434
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-11/
[children] =>
)
[information-sharing.information-sharing-information-sharing.fiocruz-astrazeneca-covid-19-technological-order-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3428
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-7/
[children] =>
)
[information-sharing.technology-transfer.fiocruz-astrazeneca-covid-19-technological-order-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 3421
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-2/
[children] =>
)
[ip-ownership.license-grants.fiocruz-astrazeneca-covid-19-technological-order-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3422
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-3/
[children] =>
)
[liability.indemnity.fiocruz-astrazeneca-covid-19-technological-order-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3436
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-13/
[children] =>
)
[liability.warranties.fiocruz-astrazeneca-covid-19-technological-order-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3430
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-8/
[children] =>
)
[term-and-termination.effect-of-termination.fiocruz-astrazeneca-covid-19-technological-order-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4601
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-12/
[children] =>
)
[term-and-termination.term-of-agreement.fiocruz-astrazeneca-covid-19-technological-order-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3426
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-5/
[children] =>
)
[term-and-termination.termination-and-withdrawal.fiocruz-astrazeneca-covid-19-technological-order-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 3431
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-9/
[children] =>
)
)
Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
2021
Government
Industry
Vaccine
Commercialization
Array
(
[access-to-medicines.donation.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 271
[slug] => donation
[title] => Donation
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Donation
[provision_id] => 3849
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5/
[children] =>
)
[access-to-medicines.pricing.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 3848
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4/
[children] =>
)
[access-to-medicines.territory-access-commitments.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 3855
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11/
[children] =>
)
[business-model.regulatory-strategy.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 3863
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19/
[children] =>
)
[business-model.roles-responsibilities.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3861
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17/
[children] =>
)
[business-model.supply-purchase-of-products.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3855
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11/
[children] =>
)
[information-sharing.confidentiality.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3851
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7/
[children] =>
)
[information-sharing.information-sharing-information-sharing.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3856
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12/
[children] =>
)
[information-sharing.publication-of-results.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 3852
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8/
[children] =>
)
[information-sharing.technology-transfer.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 3854
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10/
[children] =>
)
[ip-ownership.license-grants.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3847
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3/
[children] =>
)
[ip-ownership.ownership-ip.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3847
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3/
[children] =>
)
[ip-ownership.protection-results.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 3846
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2/
[children] =>
)
[liability.warranties.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3857
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13/
[children] =>
)
[term-and-termination.effect-of-termination.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 3860
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16/
[children] =>
)
[term-and-termination.term-of-agreement.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3858
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14/
[children] =>
)
[term-and-termination.termination-and-withdrawal.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 3859
[provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15/
[children] =>
)
)
Funder Development Partnering Agreement Template
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[access-to-medicines.ensuring-continuity.funder-development-partnering-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 1201
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-8/
[children] =>
)
[access-to-medicines.equitable-access.funder-development-partnering-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 1199
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-7/
[children] =>
)
[access-to-medicines.outbreak-preparedness.funder-development-partnering-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 102
[slug] => outbreak-preparedness
[title] => Preparedness & response
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Preparedness & response
[provision_id] => 1198
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-6/
[children] =>
)
[access-to-medicines.pricing.funder-development-partnering-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 1199
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-7/
[children] =>
)
[access-to-medicines.territory-access-commitments.funder-development-partnering-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 1199
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-7/
[children] =>
)
[business-model.benefit-revenue-sharing.funder-development-partnering-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 66
[slug] => benefit-revenue-sharing
[title] => Benefit sharing
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Benefit sharing
[provision_id] => 1200
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-9/
[children] =>
)
[business-model.regulatory-strategy.funder-development-partnering-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 1184
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-5/
[children] =>
)
[business-model.roles-responsibilities.funder-development-partnering-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 5812
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-12/
[children] =>
)
[business-model.royalties-and-payments.funder-development-partnering-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 5810
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-4/
[children] =>
)
[information-sharing.confidentiality.funder-development-partnering-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 5813
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-13/
[children] =>
)
[information-sharing.information-sharing-information-sharing.funder-development-partnering-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 5807
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-3/
[children] =>
)
[information-sharing.publication-of-results.funder-development-partnering-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 5811
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-11/
[children] =>
)
[ip-ownership.license-grants.funder-development-partnering-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1201
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-8/
[children] =>
)
[ip-ownership.ownership-ip.funder-development-partnering-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 1158
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-2/
[children] =>
)
[ip-ownership.protection-results.funder-development-partnering-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 1139
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement/
[children] =>
)
[liability.indemnity.funder-development-partnering-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1274
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-10/
[children] =>
)
[liability.insurance.funder-development-partnering-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 5827
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-15/
[children] =>
)
[liability.warranties.funder-development-partnering-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 5814
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-14/
[children] =>
)
[term-and-termination.effect-of-termination.funder-development-partnering-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 5829
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-17/
[children] =>
)
[term-and-termination.term-of-agreement.funder-development-partnering-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 5828
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-16/
[children] =>
)
[term-and-termination.termination-and-withdrawal.funder-development-partnering-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 5828
[provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-16/
[children] =>
)
)
Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
2017
Funder
Industry
Drug
Preclinical
Array
(
[access-to-medicines.ensuring-continuity.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 4681
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2/
[children] =>
)
[access-to-medicines.equitable-access.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 4680
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement/
[children] =>
)
[business-model.royalties-and-payments.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 4684
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5/
[children] =>
)
[information-sharing.confidentiality.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4682
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-3/
[children] =>
)
[information-sharing.information-sharing-information-sharing.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4691
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-11/
[children] =>
)
[information-sharing.publication-of-results.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 4683
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-4/
[children] =>
)
[ip-ownership.license-grants.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4681
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2/
[children] =>
)
[liability.indemnity.what-are-the-mechanisms-to-limit-exposure-to-additional-payments-or-expenses] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4685
[provision_permalink] => https://ghiaa.org/provision_document/what-are-the-mechanisms-to-limit-exposure-to-additional-payments-or-expenses/
[children] =>
)
[liability.insurance.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4686
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-6/
[children] =>
)
[liability.warranties.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4687
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-7/
[children] =>
)
[term-and-termination.effect-of-termination.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4690
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-10/
[children] =>
)
[term-and-termination.term-of-agreement.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4688
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-8/
[children] =>
)
[term-and-termination.termination-and-withdrawal.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4689
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-9/
[children] =>
)
)
Gates Foundation - Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
2017
Funder
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 4695
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement/
[children] =>
)
[access-to-medicines.equitable-access.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 4696
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2/
[children] =>
)
[access-to-medicines.pricing.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 4697
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3/
[children] =>
)
[access-to-medicines.territory-access-commitments.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 4697
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3/
[children] =>
)
[business-model.roles-responsibilities.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4704
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10/
[children] =>
)
[information-sharing.confidentiality.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4698
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4699
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5/
[children] =>
)
[information-sharing.publication-of-results.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 4699
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5/
[children] =>
)
[ip-ownership.license-grants.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4695
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement/
[children] =>
)
[liability.indemnity.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4700
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-6/
[children] =>
)
[liability.warranties.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4701
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-7/
[children] =>
)
[term-and-termination.effect-of-termination.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4703
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9/
[children] =>
)
[term-and-termination.termination-and-withdrawal.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4702
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-8/
[children] =>
)
)
Gates Foundation - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
2020
Funder
Industry
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 3378
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4/
[children] =>
)
[access-to-medicines.equitable-access.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 3375
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments/
[children] =>
)
[information-sharing.confidentiality.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3379
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5/
[children] =>
)
[information-sharing.information-sharing-information-sharing.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3377
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3/
[children] =>
)
[information-sharing.publication-of-results.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 3377
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3/
[children] =>
)
[ip-ownership.license-grants.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3378
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4/
[children] =>
)
[ip-ownership.ownership-ip.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-6] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 4853
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-6/
[children] =>
)
[liability.warranties.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-7] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4855
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-7/
[children] =>
)
[term-and-termination.term-of-agreement.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3376
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2/
[children] =>
)
)
Gates Foundation - CureVac, Global Access Commitments Agreement
2015
Funder
Industry
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[access-to-medicines.ensuring-continuity.bmgf-curevac-global-access-commitments-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 3357
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-8/
[children] =>
)
[access-to-medicines.equitable-access.bmgf-curevac-global-access-commitments-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 3335
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement/
[children] =>
)
[access-to-medicines.pricing.bmgf-curevac-global-access-commitments-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 3345
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-2/
[children] =>
)
[access-to-medicines.territory-access-commitments.bmgf-curevac-global-access-commitments-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 3355
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-7/
[children] =>
)
[business-model.roles-responsibilities.bmgf-curevac-global-access-commitments-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4857
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-15/
[children] =>
)
[business-model.royalties-and-payments.bmgf-curevac-global-access-commitments-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3346
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-3/
[children] =>
)
[information-sharing.confidentiality.bmgf-curevac-global-access-commitments-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3365
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-12/
[children] =>
)
[information-sharing.information-sharing-information-sharing.bmgf-curevac-global-access-commitments-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3353
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-6/
[children] =>
)
[information-sharing.publication-of-results.bmgf-curevac-global-access-commitments-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 3350
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-5/
[children] =>
)
[ip-ownership.ownership-ip.bmgf-curevac-global-access-commitments-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3347
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-4/
[children] =>
)
[ip-ownership.protection-results.bmgf-curevac-global-access-commitments-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 3347
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-4/
[children] =>
)
[liability.indemnity.bmgf-curevac-global-access-commitments-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3367
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-13/
[children] =>
)
[liability.insurance.bmgf-curevac-global-access-commitments-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 3362
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-11/
[children] =>
)
[liability.warranties.bmgf-curevac-global-access-commitments-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3359
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-10/
[children] =>
)
[term-and-termination.term-of-agreement.bmgf-curevac-global-access-commitments-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3358
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-9/
[children] =>
)
[term-and-termination.termination-and-withdrawal.bmgf-curevac-global-access-commitments-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 3369
[provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-14/
[children] =>
)
)
Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
2021
Funder
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 5592
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2/
[children] =>
)
[access-to-medicines.equitable-access.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 5599
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7/
[children] =>
)
[access-to-medicines.pricing.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 5593
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3/
[children] =>
)
[access-to-medicines.territory-access-commitments.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 5594
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4/
[children] =>
)
[business-model.supply-purchase-of-products.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 5594
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4/
[children] =>
)
[information-sharing.publication-of-results.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 5595
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5/
[children] =>
)
[ip-ownership.license-grants.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 5592
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2/
[children] =>
)
[ip-ownership.ownership-ip.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 5591
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement/
[children] =>
)
[liability.warranties.gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 5596
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6/
[children] =>
)
)
Gates Foundation - Icosavax, COVID-19 Vaccine Grant Agreement
2021
Funder
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
[access-to-medicines.ensuring-continuity.gates-foundation-icosavax-covid-19-vaccine-grant-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 5608
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement/
[children] =>
)
[access-to-medicines.equitable-access.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 5609
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2/
[children] =>
)
[business-model.royalties-and-payments.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 5612
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5/
[children] =>
)
[information-sharing.confidentiality.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 5619
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11/
[children] =>
)
[information-sharing.information-sharing-information-sharing.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 5611
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4/
[children] =>
)
[information-sharing.publication-of-results.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 5610
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3/
[children] =>
)
[ip-ownership.license-grants.gates-foundation-icosavax-covid-19-vaccine-grant-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 5608
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement/
[children] =>
)
[liability.indemnity.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 5614
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6/
[children] =>
)
[liability.insurance.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 5615
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7/
[children] =>
)
[liability.warranties.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 5620
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12/
[children] =>
)
[term-and-termination.effect-of-termination.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 5618
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10/
[children] =>
)
[term-and-termination.term-of-agreement.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 5616
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8/
[children] =>
)
[term-and-termination.termination-and-withdrawal.gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 5617
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9/
[children] =>
)
)
Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
2015
Funder
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 6635
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8/
[children] =>
)
[access-to-medicines.equitable-access.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 6628
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement/
[children] =>
)
[access-to-medicines.pricing.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 6632
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-5/
[children] =>
)
[access-to-medicines.territory-access-commitments.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 6631
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-4/
[children] =>
)
[business-model.roles-responsibilities.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 6630
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3/
[children] =>
)
[information-sharing.confidentiality.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 6638
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-11/
[children] =>
)
[information-sharing.information-sharing-information-sharing.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 6630
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3/
[children] =>
)
[information-sharing.publication-of-results.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 6629
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-2/
[children] =>
)
[information-sharing.technology-transfer.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 6636
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-9/
[children] =>
)
[liability.indemnity.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 6637
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-10/
[children] =>
)
[liability.warranties.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 6633
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-6/
[children] =>
)
[term-and-termination.effect-of-termination.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 6634
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7/
[children] =>
)
[term-and-termination.term-of-agreement.gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 6634
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7/
[children] =>
)
)
Gates Foundation Sample Grant Terms & Conditions
2019
Academic institution
Funder
Industry
Product development partnership
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[access-to-medicines.ensuring-continuity.gates-global-access-commitment-and-humanitarian-license] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 1206
[provision_permalink] => https://ghiaa.org/provision_document/gates-global-access-commitment-and-humanitarian-license/
[children] =>
)
[access-to-medicines.equitable-access.gates-foundation-sample-grant-terms-conditions] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 4519
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-grant-terms-conditions/
[children] =>
)
[information-sharing.confidentiality.gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 1395
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2/
[children] =>
)
[information-sharing.publication-of-results.gates-foundation-sample-terms-conditions] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 1394
[provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-terms-conditions/
[children] =>
)
[ip-ownership.license-grants.gates-global-access-commitment-and-humanitarian-license] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1206
[provision_permalink] => https://ghiaa.org/provision_document/gates-global-access-commitment-and-humanitarian-license/
[children] =>
)
)
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 4150
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3/
[children] =>
)
[access-to-medicines.equitable-access.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 4147
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15/
[children] =>
)
[access-to-medicines.outbreak-preparedness.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 102
[slug] => outbreak-preparedness
[title] => Preparedness & response
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Preparedness & response
[provision_id] => 5808
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16/
[children] =>
)
[access-to-medicines.pricing.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 4149
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2/
[children] =>
)
[access-to-medicines.territory-access-commitments.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 4148
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13/
[children] =>
)
[business-model.regulatory-strategy.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 4161
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14/
[children] =>
)
[business-model.roles-responsibilities.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4159
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12/
[children] =>
)
[business-model.royalties-and-payments.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 4149
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2/
[children] =>
)
[business-model.supply-purchase-of-products.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 4148
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13/
[children] =>
)
[information-sharing.confidentiality.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4151
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4152
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5/
[children] =>
)
[ip-ownership.license-grants.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4146
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement/
[children] =>
)
[ip-ownership.ownership-ip.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 4146
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement/
[children] =>
)
[liability.indemnity.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4153
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6/
[children] =>
)
[liability.insurance.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4154
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7/
[children] =>
)
[liability.warranties.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4155
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8/
[children] =>
)
[term-and-termination.effect-of-termination.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4158
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11/
[children] =>
)
[term-and-termination.term-of-agreement.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4156
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9/
[children] =>
)
[term-and-termination.termination-and-withdrawal.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4157
[provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10/
[children] =>
)
)
Gilead - Indian Generic Manufacturers, HCV License Agreement
2014
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[business-model.royalties-and-payments.gilead-indian-generic-manufacturers-hcv-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3691
[provision_permalink] => https://ghiaa.org/provision_document/gilead-indian-generic-manufacturers-hcv-license-agreement-2/
[children] =>
)
[information-sharing.technology-transfer.gilead-indian-generic-manufacturers-hcv-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 3694
[provision_permalink] => https://ghiaa.org/provision_document/gilead-indian-generic-manufacturers-hcv-license-agreement-4/
[children] =>
)
[ip-ownership.license-grants.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1145
[provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
[children] =>
)
[ip-ownership.ownership-ip.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 1145
[provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
[children] =>
)
[ip-ownership.protection-results.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 1145
[provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
[children] =>
)
[liability.indemnity.gilead-indian-generic-manufacturers-hcv-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3689
[provision_permalink] => https://ghiaa.org/provision_document/gilead-indian-generic-manufacturers-hcv-license-agreement/
[children] =>
)
[liability.insurance.gilead-hcv-license-agreement-with-indian-generic-manufacturers-3] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 1264
[provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-3/
[children] =>
)
)
Gilead - MPP - Arene Lifesciences, HIV Therapeutic License Agreement
2018
Industry
Multilateral organization
Drug
Commercialization
Array
(
[access-to-medicines.territory-access-commitments.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 5800
[provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3/
[children] =>
)
[business-model.regulatory-strategy.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 5800
[provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3/
[children] =>
)
[business-model.roles-responsibilities.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 5806
[provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-8/
[children] =>
)
[business-model.royalties-and-payments.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 5798
[provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement/
[children] =>
)
[information-sharing.confidentiality.mpp-license-agreement-with-gilead-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 1249
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.gilead-mpp-tdf-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 5790
[provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-tdf-license-agreement/
[children] =>
)
[information-sharing.technology-transfer.mpp-license-agreement-with-gilead-3] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 1228
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-3/
[children] =>
)
[ip-ownership.license-grants.mpp-license-agreement-with-gilead] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1114
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead/
[children] =>
)
[ip-ownership.protection-results.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 5799
[provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-2/
[children] =>
)
[liability.indemnity.mpp-license-agreement-with-gilead-5] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1263
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-5/
[children] =>
)
[liability.insurance.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 5803
[provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-5/
[children] =>
)
[liability.warranties.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 5802
[provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-4/
[children] =>
)
[term-and-termination.effect-of-termination.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 5805
[provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-7/
[children] =>
)
[term-and-termination.term-of-agreement.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 5804
[provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-6/
[children] =>
)
[term-and-termination.termination-and-withdrawal.gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 5805
[provision_permalink] => https://ghiaa.org/provision_document/gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-7/
[children] =>
)
)
IMI 1 Model Grant Agreement
2011
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[ip-ownership.license-grants.imi-1-model-grant-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1171
[provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement-3/
[children] =>
)
[ip-ownership.ownership-ip.imi-1-model-grant-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 1111
[provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement/
[children] =>
)
)
IMI 2 JU Model Consortium Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[information-sharing.confidentiality.imi-2-joint-undertaking-model-consortium-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 1245
[provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-5/
[children] =>
)
[information-sharing.technology-transfer.imi-2-joint-undertaking-model-consortium-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 1237
[provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-4/
[children] =>
)
[ip-ownership.license-grants.imi-2joint-undertaking-model-consortium-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1309
[provision_permalink] => https://ghiaa.org/provision_document/imi-2joint-undertaking-model-consortium-agreement/
[children] =>
)
[ip-ownership.ownership-ip.imi-2joint-undertaking-model-consortium-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 1309
[provision_permalink] => https://ghiaa.org/provision_document/imi-2joint-undertaking-model-consortium-agreement/
[children] =>
)
[ip-ownership.protection-results.imi-2-joint-undertaking-model-consortium-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 1166
[provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-2/
[children] =>
)
[liability.indemnity.imi-2-joint-undertaking-model-consortium-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1266
[provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-8/
[children] =>
)
)
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[access-to-medicines.ensuring-continuity.imi-2-model-grant-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 1178
[provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-5/
[children] =>
)
[information-sharing.confidentiality.imi-2-model-grant-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 1253
[provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-8/
[children] =>
)
[information-sharing.publication-of-results.imi-2-model-grant-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 1211
[provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-6/
[children] =>
)
[ip-ownership.license-grants.imi-2-model-grant-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1128
[provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement/
[children] =>
)
[ip-ownership.ownership-ip.imi-2-model-grant-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 1308
[provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-12/
[children] =>
)
[ip-ownership.protection-results.imi-2-model-grant-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 1165
[provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-3/
[children] =>
)
[liability.indemnity.imi-2-model-grant-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1268
[provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-9/
[children] =>
)
)
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[business-model.roles-responsibilities.2867] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 2867
[provision_permalink] => https://ghiaa.org/provision_document/2867/
[children] =>
)
[business-model.royalties-and-payments.2867] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 2867
[provision_permalink] => https://ghiaa.org/provision_document/2867/
[children] =>
)
[information-sharing.confidentiality.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 2869
[provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3/
[children] =>
)
[information-sharing.information-sharing-information-sharing.2867] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 2867
[provision_permalink] => https://ghiaa.org/provision_document/2867/
[children] =>
)
[information-sharing.publication-of-results.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 2873
[provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6/
[children] =>
)
[ip-ownership.ownership-ip.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 2872
[provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5/
[children] =>
)
[liability.warranties.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 2870
[provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4/
[children] =>
)
)
Lambert Toolkit, Consortium Agreement D Template
2019
Academic institution
Industry
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[information-sharing.confidentiality.lambert-agreement-d-5] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 1239
[provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-5/
[children] =>
)
[information-sharing.publication-of-results.lambert-agreement-d-14] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 1214
[provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-14/
[children] =>
)
[ip-ownership.license-grants.lambert-agreement-d-3] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1177
[provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-3/
[children] =>
)
[ip-ownership.ownership-ip.lambert-agreement-d] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 1107
[provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d/
[children] =>
)
[liability.indemnity.lambert-agreement-d-10] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1262
[provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-10/
[children] =>
)
[liability.warranties.lambert-agreement-d-8] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 1258
[provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-8/
[children] =>
)
[term-and-termination.termination-and-withdrawal.lambert-agreement-d-12] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 1281
[provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-12/
[children] =>
)
)
Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
2014
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[information-sharing.confidentiality.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 1242
[provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6/
[children] =>
)
[information-sharing.technology-transfer.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 1235
[provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4/
[children] =>
)
[ip-ownership.license-grants.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1140
[provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2/
[children] =>
)
[ip-ownership.ownership-ip.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 1112
[provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation/
[children] =>
)
[liability.indemnity.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1267
[provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7/
[children] =>
)
[term-and-termination.effect-of-termination.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 1287
[provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10/
[children] =>
)
[term-and-termination.term-of-agreement.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 1285
[provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9/
[children] =>
)
[term-and-termination.termination-and-withdrawal.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 1285
[provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9/
[children] =>
)
)
Merck - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.pricing.msd-mpp-molnupiravir-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 3899
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-8/
[children] =>
)
[access-to-medicines.territory-access-commitments.msd-mpp-molnupiravir-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 3895
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-4/
[children] =>
)
[business-model.regulatory-strategy.msd-mpp-molnupiravir-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 3910
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement/
[children] =>
)
[business-model.roles-responsibilities.msd-mpp-molnupiravir-license-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3909
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-17/
[children] =>
)
[business-model.royalties-and-payments.msd-mpp-molnupiravir-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3899
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-8/
[children] =>
)
[business-model.supply-purchase-of-products.msd-mpp-molnupiravir-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3898
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-7/
[children] =>
)
[information-sharing.confidentiality.msd-mpp-molnupiravir-license-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3896
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-5/
[children] =>
)
[information-sharing.information-sharing-information-sharing.msd-mpp-molnupiravir-license-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3908
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-16/
[children] =>
)
[information-sharing.technology-transfer.msd-mpp-molnupiravir-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 3897
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-6/
[children] =>
)
[ip-ownership.license-grants.msd-mpp-molnupiravir-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3892
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-3/
[children] =>
)
[ip-ownership.ownership-ip.msd-mpp-molnupiravir-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3892
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-3/
[children] =>
)
[ip-ownership.protection-results.msd-mpp-molnupiravir-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 3891
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-2/
[children] =>
)
[liability.indemnity.msd-mpp-molnupiravir-license-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3900
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-9/
[children] =>
)
[liability.insurance.msd-mpp-molnupiravir-license-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 3901
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-10/
[children] =>
)
[liability.warranties.msd-mpp-molnupiravir-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3903
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-12/
[children] =>
)
[term-and-termination.effect-of-termination.msd-mpp-molnupiravir-license-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 3907
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-15/
[children] =>
)
[term-and-termination.term-of-agreement.msd-mpp-molnupiravir-license-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3904
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-13/
[children] =>
)
[term-and-termination.termination-and-withdrawal.msd-mpp-molnupiravir-license-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 3906
[provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-14/
[children] =>
)
)
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[business-model.regulatory-strategy.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 3886
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16/
[children] =>
)
[business-model.roles-responsibilities.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3884
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14/
[children] =>
)
[business-model.royalties-and-payments.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3876
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6/
[children] =>
)
[business-model.supply-purchase-of-products.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3875
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5/
[children] =>
)
[information-sharing.confidentiality.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3873
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4/
[children] =>
)
[information-sharing.technology-transfer.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 3874
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2/
[children] =>
)
[ip-ownership.license-grants.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3869
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17/
[children] =>
)
[ip-ownership.ownership-ip.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3869
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17/
[children] =>
)
[ip-ownership.protection-results.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 3870
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement/
[children] =>
)
[liability.indemnity.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3877
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7/
[children] =>
)
[liability.insurance.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 3878
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8/
[children] =>
)
[liability.warranties.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3880
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10/
[children] =>
)
[term-and-termination.effect-of-termination.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 3883
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13/
[children] =>
)
[term-and-termination.term-of-agreement.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3881
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11/
[children] =>
)
[term-and-termination.termination-and-withdrawal.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 3882
[provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12/
[children] =>
)
)
MPP - AbbVie, HIV Antiretroviral License Agreement
2016
Industry
Multilateral organization
Drug
Commercialization
Array
(
[ip-ownership.license-grants.mpps-license-agreement-with-abbvie] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1118
[provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-abbvie/
[children] =>
)
)
MPP - AbbVie, HIV Antiretroviral Sublicense Agreement
2014
Industry
Multilateral organization
Drug
Commercialization
Array
(
[access-to-medicines.territory-access-commitments.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 1125
[provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2/
[children] =>
)
[ip-ownership.license-grants.mpp-license-agreement-with-abbvie] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1183
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-abbvie/
[children] =>
)
[liability.indemnity.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1313
[provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3/
[children] =>
)
)
MPP - BMS - Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
2016
Industry
Multilateral organization
Drug
Commercialization
Array
(
[access-to-medicines.pricing.mpp-license-agreement-with-bms-aurobindo-pharma-ltd] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 1122
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd/
[children] =>
)
[access-to-medicines.territory-access-commitments.mpp-license-agreement-with-bms-aurobindo-pharma-ltd] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 1122
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd/
[children] =>
)
[information-sharing.technology-transfer.mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 1229
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2/
[children] =>
)
)
MPP - BMS Sublicense & Tech Transfer Agreement
2017
Industry
Multilateral organization
Drug
Commercialization
Array
(
[business-model.regulatory-strategy.mpp-bms-sublicense-tech-transfer-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 3914
[provision_permalink] => https://ghiaa.org/provision_document/mpp-bms-sublicense-tech-transfer-agreement/
[children] =>
)
[ip-ownership.license-grants.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1124
[provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement/
[children] =>
)
[liability.indemnity.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1314
[provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2/
[children] =>
)
[liability.insurance.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 1314
[provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2/
[children] =>
)
[term-and-termination.term-of-agreement.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 1124
[provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement/
[children] =>
)
)
MPP - Merck, Raltegravir License Agreement
2015
Industry
Multilateral organization
Drug
Commercialization
MPP - Pfizer, Sutezolid License Agreement
2019
Industry
Multilateral organization
Drug
Commercialization
Array
(
[access-to-medicines.pricing.mpp-license-agreement-with-pfizer-re-sutezolid] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 1207
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-pfizer-re-sutezolid/
[children] =>
)
[access-to-medicines.territory-access-commitments.mpp-license-agreement-with-pfizer-re-sutezolid] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 1207
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-pfizer-re-sutezolid/
[children] =>
)
)
MPP - University of Liverpool, Solid Drug Nanoparticle Technology License Agreement
2015
Academic institution
Multilateral organization
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[access-to-medicines.pricing.mpps-license-agreement-with-university-of-liverpool] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 1117
[provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-university-of-liverpool/
[children] =>
)
[business-model.royalties-and-payments.mpps-license-agreement-with-university-of-liverpool] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 1117
[provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-university-of-liverpool/
[children] =>
)
)
MPP - ViiV, Dolutegravir License Agreement
2016
Industry
Multilateral organization
Drug
Commercialization
Array
(
[ip-ownership.license-grants.mpp-license-agreement-with-viiv-on-dolutegravir-for-adults] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1123
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-viiv-on-dolutegravir-for-adults/
[children] =>
)
[liability.indemnity.mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1315
[provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2/
[children] =>
)
)
MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
2022
Industry
Multilateral organization
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 9062
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2/
[children] =>
)
[business-model.roles-responsibilities.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 9068
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8/
[children] =>
)
[business-model.royalties-and-payments.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 9067
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7/
[children] =>
)
[information-sharing.confidentiality.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 9064
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 9066
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6/
[children] =>
)
[information-sharing.publication-of-results.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 9065
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5/
[children] =>
)
[ip-ownership.license-grants.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 9062
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2/
[children] =>
)
[ip-ownership.ownership-ip.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 9061
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement/
[children] =>
)
[ip-ownership.protection-results.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 9063
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3/
[children] =>
)
[liability.indemnity.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 9069
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9/
[children] =>
)
[liability.insurance.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 9070
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10/
[children] =>
)
[liability.warranties.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 9071
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11/
[children] =>
)
[term-and-termination.effect-of-termination.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 9073
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13/
[children] =>
)
[term-and-termination.term-of-agreement.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 9072
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12/
[children] =>
)
[term-and-termination.termination-and-withdrawal.mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 9073
[provision_permalink] => https://ghiaa.org/provision_document/mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13/
[children] =>
)
)
MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
2022
Industry
Multilateral organization
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 9077
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2/
[children] =>
)
[business-model.roles-responsibilities.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 9083
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8/
[children] =>
)
[business-model.royalties-and-payments.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 9082
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7/
[children] =>
)
[information-sharing.confidentiality.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 9079
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 9081
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6/
[children] =>
)
[information-sharing.publication-of-results.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 9080
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5/
[children] =>
)
[ip-ownership.license-grants.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 9077
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2/
[children] =>
)
[ip-ownership.ownership-ip.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 9076
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement/
[children] =>
)
[ip-ownership.protection-results.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 9078
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3/
[children] =>
)
[liability.indemnity.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 9086
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9/
[children] =>
)
[liability.insurance.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 9087
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10/
[children] =>
)
[liability.warranties.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 9088
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11/
[children] =>
)
[term-and-termination.effect-of-termination.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 9090
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13/
[children] =>
)
[term-and-termination.term-of-agreement.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 9089
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12/
[children] =>
)
[term-and-termination.termination-and-withdrawal.mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 9090
[provision_permalink] => https://ghiaa.org/provision_document/mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13/
[children] =>
)
)
National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement
2022
Government
Industry
Drug
Commercialization
Array
(
[business-model.regulatory-strategy.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 9022
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-7/
[children] =>
)
[business-model.roles-responsibilities.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 9021
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-6/
[children] =>
)
[business-model.royalties-and-payments.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 9016
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-5/
[children] =>
)
[business-model.supply-purchase-of-products.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 9015
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-4/
[children] =>
)
[information-sharing.confidentiality.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 9013
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-2/
[children] =>
)
[information-sharing.information-sharing-information-sharing.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 9014
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-3/
[children] =>
)
[ip-ownership.license-grants.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 9012
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement/
[children] =>
)
[liability.indemnity.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 9023
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-8/
[children] =>
)
[liability.insurance.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 9024
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-9/
[children] =>
)
[liability.warranties.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 9025
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-10/
[children] =>
)
[term-and-termination.effect-of-termination.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 9028
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-13/
[children] =>
)
[term-and-termination.term-of-agreement.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 9026
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-11/
[children] =>
)
[term-and-termination.termination-and-withdrawal.national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 9027
[provision_permalink] => https://ghiaa.org/provision_document/national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-12/
[children] =>
)
)
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Vaccine
Preclinical
Commercialization
Array
(
[access-to-medicines.territory-access-commitments.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 3414
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8/
[children] =>
)
[business-model.roles-responsibilities.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3418
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12/
[children] =>
)
[business-model.royalties-and-payments.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3410
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4/
[children] =>
)
[business-model.supply-purchase-of-products.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3414
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8/
[children] =>
)
[information-sharing.confidentiality.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3413
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7/
[children] =>
)
[information-sharing.information-sharing-information-sharing.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3412
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6/
[children] =>
)
[information-sharing.publication-of-results.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 3412
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6/
[children] =>
)
[ip-ownership.license-grants.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3406
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement/
[children] =>
)
[ip-ownership.protection-results.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 3411
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5/
[children] =>
)
[liability.indemnity.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3415
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9/
[children] =>
)
[liability.warranties.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3415
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9/
[children] =>
)
[term-and-termination.effect-of-termination.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 3417
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11/
[children] =>
)
[term-and-termination.term-of-agreement.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3416
[provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10/
[children] =>
)
)
NIH - MPP, COVID-19 Patent and Biological Material License Agreement
2022
Government
Multilateral organization
Diagnostic
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.equitable-access.nih-mpp-covid-19-patent-and-biological-material-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 5114
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-4/
[children] =>
)
[access-to-medicines.pricing.nih-mpp-covid-19-patent-and-biological-material-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 5113
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-3/
[children] =>
)
[access-to-medicines.territory-access-commitments.nih-mpp-covid-19-patent-and-biological-material-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 5123
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-12/
[children] =>
)
[business-model.roles-responsibilities.5122] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 5122
[provision_permalink] => https://ghiaa.org/provision_document/5122/
[children] =>
)
[business-model.royalties-and-payments.nih-mpp-covid-19-patent-and-biological-material-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 5113
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-3/
[children] =>
)
[business-model.supply-purchase-of-products.nih-mpp-covid-19-patent-and-biological-material-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 5123
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-12/
[children] =>
)
[information-sharing.confidentiality.nih-mpp-covid-19-patent-and-biological-material-license-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 5115
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-5/
[children] =>
)
[information-sharing.information-sharing-information-sharing.nih-mpp-covid-19-patent-and-biological-material-license-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 5121
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-11/
[children] =>
)
[information-sharing.publication-of-results.nih-mpp-covid-19-patent-and-biological-material-license-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 5121
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-11/
[children] =>
)
[ip-ownership.license-grants.nih-mpp-covid-19-patent-and-biological-material-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 5111
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement/
[children] =>
)
[ip-ownership.ownership-ip.nih-mpp-covid-19-patent-and-biological-material-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 5111
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement/
[children] =>
)
[ip-ownership.protection-results.nih-mpp-covid-19-patent-and-biological-material-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 5112
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-2/
[children] =>
)
[liability.indemnity.nih-mpp-covid-19-patent-and-biological-material-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 5116
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-6/
[children] =>
)
[liability.insurance.nih-mpp-covid-19-patent-and-biological-material-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 5117
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-7/
[children] =>
)
[liability.warranties.nih-mpp-covid-19-patent-and-biological-material-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 5118
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-8/
[children] =>
)
[term-and-termination.effect-of-termination.nih-mpp-covid-19-patent-and-biological-material-license-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 5120
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-10/
[children] =>
)
[term-and-termination.term-of-agreement.nih-mpp-covid-19-patent-and-biological-material-license-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 5119
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-9/
[children] =>
)
[term-and-termination.termination-and-withdrawal.nih-mpp-covid-19-patent-and-biological-material-license-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 5120
[provision_permalink] => https://ghiaa.org/provision_document/nih-mpp-covid-19-patent-and-biological-material-license-agreement-10/
[children] =>
)
)
NIH - Non-Profit, Model License Agreement Terms
2017
Government
Multilateral organization
Product development partnership
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[ip-ownership.license-grants.nih-model-license-agreement-for-use-by-non-profit] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1135
[provision_permalink] => https://ghiaa.org/provision_document/nih-model-license-agreement-for-use-by-non-profit/
[children] =>
)
[ip-ownership.protection-results.nih-model-license-agreement-for-use-by-non-profit-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 1168
[provision_permalink] => https://ghiaa.org/provision_document/nih-model-license-agreement-for-use-by-non-profit-2/
[children] =>
)
)
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 3808
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13/
[children] =>
)
[access-to-medicines.territory-access-commitments.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 3806
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11/
[children] =>
)
[business-model.regulatory-strategy.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 3807
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12/
[children] =>
)
[business-model.roles-responsibilities.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3810
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15/
[children] =>
)
[business-model.royalties-and-payments.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3801
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6/
[children] =>
)
[business-model.supply-purchase-of-products.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3809
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14/
[children] =>
)
[information-sharing.confidentiality.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3799
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4661
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16/
[children] =>
)
[information-sharing.technology-transfer.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 3800
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5/
[children] =>
)
[ip-ownership.license-grants.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3796
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement/
[children] =>
)
[ip-ownership.ownership-ip.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3797
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2/
[children] =>
)
[ip-ownership.protection-results.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 3798
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3/
[children] =>
)
[liability.indemnity.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3802
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7/
[children] =>
)
[liability.insurance.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 3803
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8/
[children] =>
)
[liability.warranties.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3812
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17/
[children] =>
)
[term-and-termination.effect-of-termination.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 3805
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10/
[children] =>
)
[term-and-termination.term-of-agreement.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3804
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9/
[children] =>
)
[term-and-termination.termination-and-withdrawal.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 3804
[provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9/
[children] =>
)
)
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
[business-model.regulatory-strategy.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 4054
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20/
[children] =>
)
[business-model.roles-responsibilities.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4051
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17/
[children] =>
)
[business-model.royalties-and-payments.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 4040
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8/
[children] =>
)
[business-model.supply-purchase-of-products.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 4041
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9/
[children] =>
)
[information-sharing.confidentiality.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4032
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3/
[children] =>
)
[information-sharing.information-sharing-information-sharing.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4036
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5/
[children] =>
)
[information-sharing.publication-of-results.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 4035
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4/
[children] =>
)
[information-sharing.technology-transfer.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 4038
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7/
[children] =>
)
[ip-ownership.license-grants.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4029
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2/
[children] =>
)
[ip-ownership.ownership-ip.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 4028
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement/
[children] =>
)
[liability.indemnity.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4042
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10/
[children] =>
)
[liability.insurance.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4043
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11/
[children] =>
)
[liability.warranties.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4045
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13/
[children] =>
)
[term-and-termination.effect-of-termination.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4050
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16/
[children] =>
)
[term-and-termination.term-of-agreement.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4046
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14/
[children] =>
)
[term-and-termination.termination-and-withdrawal.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4047
[provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15/
[children] =>
)
)
PATH - Aridis, Rotavirus Vaccine Development Agreement
2007
Industry
Product development partnership
Vaccine
Early clinical (through Phase 2)
Array
(
[access-to-medicines.ensuring-continuity.path-aridis-rotavirus-vaccine-development-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 5809
[provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-8/
[children] =>
)
[access-to-medicines.equitable-access.path-aridis-rotavirus-vaccine-development-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 4060
[provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement/
[children] =>
)
[access-to-medicines.pricing.aridis-path-vaccine-formulation-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 1190
[provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-2/
[children] =>
)
[access-to-medicines.territory-access-commitments.aridis-path-vaccine-formulation-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 1190
[provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-2/
[children] =>
)
[business-model.roles-responsibilities.path-aridis-rotavirus-vaccine-development-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4061
[provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-2/
[children] =>
)
[business-model.royalties-and-payments.path-aridis-rotavirus-vaccine-development-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 4063
[provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-4/
[children] =>
)
[information-sharing.confidentiality.aridis-path-vaccine-formulation-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 1240
[provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.path-aridis-rotavirus-vaccine-development-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4062
[provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-3/
[children] =>
)
[information-sharing.publication-of-results.path-aridis-rotavirus-vaccine-development-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 4066
[provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-7/
[children] =>
)
[ip-ownership.license-grants.aridis-path-vaccine-formulation-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 1176
[provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement/
[children] =>
)
[ip-ownership.ownership-ip.aridis-path-vaccine-formulation-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 1160
[provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-8/
[children] =>
)
[ip-ownership.protection-results.aridis-path-vaccine-formulation-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 1160
[provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-8/
[children] =>
)
[liability.indemnity.aridis-path-vaccine-formulation-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 1275
[provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-5/
[children] =>
)
[liability.insurance.path-aridis-rotavirus-vaccine-development-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4065
[provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-6/
[children] =>
)
[liability.warranties.path-aridis-rotavirus-vaccine-development-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4064
[provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-5/
[children] =>
)
[term-and-termination.effect-of-termination.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 1283
[provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
[children] =>
)
[term-and-termination.term-of-agreement.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 1283
[provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
[children] =>
)
[term-and-termination.termination-and-withdrawal.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 1283
[provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
[children] =>
)
)
Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
[business-model.roles-responsibilities.pfizer-peru-covid-19-vaccine-binding-term-sheet-6] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3220
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-6/
[children] =>
)
[business-model.supply-purchase-of-products.pfizer-peru-covid-19-vaccine-binding-term-sheet-3] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3217
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-3/
[children] =>
)
[information-sharing.confidentiality.pfizer-peru-covid-19-vaccine-binding-term-sheet-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3218
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.pfizer-peru-covid-19-vaccine-binding-term-sheet-7] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3221
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-7/
[children] =>
)
[ip-ownership.ownership-ip.pfizer-peru-covid-19-vaccine-binding-term-sheet] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3215
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet/
[children] =>
)
[liability.indemnity.pfizer-peru-covid-19-vaccine-binding-term-sheet-5] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3219
[provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-5/
[children] =>
)
)
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
[business-model.royalties-and-payments.sanofi-translate-bio-influenza-and-covid-19-vaccine-collaboration-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 5429
[provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-influenza-and-covid-19-vaccine-collaboration-license-agreement/
[children] =>
)
[information-sharing.technology-transfer.sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 2426
[provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3/
[children] =>
)
[ip-ownership.ownership-ip.sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 2424
[provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2/
[children] =>
)
)
Shionogi - GARDP, Cefiderocol License Agreement
2022
Industry
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.equitable-access.shionogi-gardp-cefiderocol-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 5272
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-4/
[children] =>
)
[access-to-medicines.territory-access-commitments.shionogi-gardp-cefiderocol-license-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 5273
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-5/
[children] =>
)
[business-model.regulatory-strategy.shionogi-gardp-cefiderocol-license-agreement-13] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 5281
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-13/
[children] =>
)
[business-model.roles-responsibilities.shionogi-gardp-cefiderocol-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 5280
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-12/
[children] =>
)
[business-model.royalties-and-payments.shionogi-gardp-cefiderocol-license-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 5279
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-11/
[children] =>
)
[business-model.supply-purchase-of-products.shionogi-gardp-cefiderocol-license-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 5278
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-10/
[children] =>
)
[information-sharing.confidentiality.shionogi-gardp-cefiderocol-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 5274
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-6/
[children] =>
)
[information-sharing.information-sharing-information-sharing.shionogi-gardp-cefiderocol-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 5276
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-8/
[children] =>
)
[information-sharing.publication-of-results.shionogi-gardp-cefiderocol-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 5275
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-7/
[children] =>
)
[information-sharing.technology-transfer.shionogi-gardp-cefiderocol-license-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 5277
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-9/
[children] =>
)
[ip-ownership.license-grants.shionogi-gardp-cefiderocol-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 5270
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-2/
[children] =>
)
[ip-ownership.ownership-ip.shionogi-gardp-cefiderocol-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 5269
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement/
[children] =>
)
[ip-ownership.protection-results.shionogi-gardp-cefiderocol-license-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 5271
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-3/
[children] =>
)
[liability.indemnity.shionogi-gardp-cefiderocol-license-agreement-14] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 5282
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-14/
[children] =>
)
[liability.insurance.shionogi-gardp-cefiderocol-license-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 5283
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-15/
[children] =>
)
[liability.warranties.shionogi-gardp-cefiderocol-license-agreement-16] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 5284
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-16/
[children] =>
)
[term-and-termination.effect-of-termination.shionogi-gardp-cefiderocol-license-agreement-18] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 5286
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-18/
[children] =>
)
[term-and-termination.term-of-agreement.shionogi-gardp-cefiderocol-license-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 5285
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-17/
[children] =>
)
[term-and-termination.termination-and-withdrawal.shionogi-gardp-cefiderocol-license-agreement-17] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 5285
[provision_permalink] => https://ghiaa.org/provision_document/shionogi-gardp-cefiderocol-license-agreement-17/
[children] =>
)
)
UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Vaccine
Commercialization
Array
(
[access-to-medicines.donation.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7] => GHIAA2019\IssueItem Object
(
[ID] => 271
[slug] => donation
[title] => Donation
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Donation
[provision_id] => 2964
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7/
[children] =>
)
[business-model.regulatory-strategy.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 2965
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10/
[children] =>
)
[business-model.royalties-and-payments.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 2947
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9/
[children] =>
)
[business-model.supply-purchase-of-products.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 2949
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5/
[children] =>
)
[information-sharing.confidentiality.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 2956
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12/
[children] =>
)
[ip-ownership.ownership-ip.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 2945
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222/
[children] =>
)
[liability.indemnity.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 2957
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4/
[children] =>
)
[liability.warranties.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 2958
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6/
[children] =>
)
[term-and-termination.effect-of-termination.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 2962
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3/
[children] =>
)
[term-and-termination.term-of-agreement.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 2960
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8/
[children] =>
)
[term-and-termination.termination-and-withdrawal.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 2961
[provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11/
[children] =>
)
)
UK Secretary of State - Roche, REGN-COV2 Supply Agreement
2021
Government
Industry
Drug
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.donation.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2] => GHIAA2019\IssueItem Object
(
[ID] => 271
[slug] => donation
[title] => Donation
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Donation
[provision_id] => 3304
[provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2/
[children] =>
)
[business-model.regulatory-strategy.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-3] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 3305
[provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-3/
[children] =>
)
[business-model.roles-responsibilities.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3303
[provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes/
[children] =>
)
[business-model.royalties-and-payments.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-9] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3312
[provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-9/
[children] =>
)
[business-model.supply-purchase-of-products.3302] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3302
[provision_permalink] => https://ghiaa.org/provision_document/3302/
[children] =>
)
[information-sharing.confidentiality.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-7] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3310
[provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-7/
[children] =>
)
[ip-ownership.ownership-ip.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-6] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3309
[provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-6/
[children] =>
)
[liability.warranties.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-5] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3308
[provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-5/
[children] =>
)
[term-and-termination.term-of-agreement.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-4] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3307
[provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-4/
[children] =>
)
[term-and-termination.termination-and-withdrawal.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-4] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 3307
[provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-4/
[children] =>
)
)
UnitaidExplore Sample Funding Terms and Conditions
2020
Academic institution
Funder
Industry
Product development partnership
Device
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.unitaidexplore-sample-funding-terms-and-conditions-6] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 7445
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-6/
[children] =>
)
[access-to-medicines.equitable-access.unitaidexplore-sample-funding-terms-and-conditions-3] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 7444
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-3/
[children] =>
)
[access-to-medicines.pricing.unitaidexplore-sample-funding-terms-and-conditions-3] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 7444
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-3/
[children] =>
)
[access-to-medicines.territory-access-commitments.unitaidexplore-sample-funding-terms-and-conditions-3] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 7444
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-3/
[children] =>
)
[business-model.roles-responsibilities.unitaidexplore-sample-funding-terms-and-conditions-10] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 7468
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-10/
[children] =>
)
[business-model.royalties-and-payments.unitaidexplore-sample-funding-terms-and-conditions] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 7442
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions/
[children] =>
)
[information-sharing.confidentiality.unitaidexplore-sample-funding-terms-and-conditions-9] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 7467
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-9/
[children] =>
)
[information-sharing.information-sharing-information-sharing.unitaidexplore-sample-funding-terms-and-conditions-4] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 7462
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-4/
[children] =>
)
[information-sharing.publication-of-results.unitaidexplore-sample-funding-terms-and-conditions-4] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 7462
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-4/
[children] =>
)
[ip-ownership.license-grants.unitaidexplore-sample-funding-terms-and-conditions-4] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 7462
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-4/
[children] =>
)
[liability.indemnity.unitaidexplore-sample-funding-terms-and-conditions-8] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 7466
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-8/
[children] =>
)
[liability.insurance.unitaidexplore-sample-funding-terms-and-conditions-5] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 7463
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-5/
[children] =>
)
[liability.warranties.unitaidexplore-sample-funding-terms-and-conditions-2] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 7443
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-2/
[children] =>
)
[term-and-termination.effect-of-termination.unitaidexplore-sample-funding-terms-and-conditions-7] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 7464
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-7/
[children] =>
)
[term-and-termination.term-of-agreement.unitaidexplore-sample-funding-terms-and-conditions-7] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 7464
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-7/
[children] =>
)
[term-and-termination.termination-and-withdrawal.unitaidexplore-sample-funding-terms-and-conditions-7] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 7464
[provision_permalink] => https://ghiaa.org/provision_document/unitaidexplore-sample-funding-terms-and-conditions-7/
[children] =>
)
)
University of Washington - Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
2021
Academic institution
Multilateral organization
Drug
Preclinical
Array
(
[access-to-medicines.equitable-access.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 101
[slug] => equitable-access
[title] => Access plans & principles
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Access plans & principles
[provision_id] => 4077
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4/
[children] =>
)
[access-to-medicines.pricing.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 4077
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4/
[children] =>
)
[access-to-medicines.territory-access-commitments.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 282
[slug] => territory-access-commitments
[title] => Territory access commitments
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Territory access commitments
[provision_id] => 4077
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4/
[children] =>
)
[business-model.regulatory-strategy.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-15] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 4089
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-15/
[children] =>
)
[business-model.roles-responsibilities.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 4079
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6/
[children] =>
)
[business-model.supply-purchase-of-products.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 4080
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-7/
[children] =>
)
[information-sharing.confidentiality.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 4078
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-5/
[children] =>
)
[information-sharing.information-sharing-information-sharing.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 4079
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6/
[children] =>
)
[information-sharing.technology-transfer.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6] => GHIAA2019\IssueItem Object
(
[ID] => 86
[slug] => technology-transfer
[title] => Technology transfer
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Technology transfer
[provision_id] => 4079
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6/
[children] =>
)
[ip-ownership.license-grants.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 4072
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement/
[children] =>
)
[ip-ownership.ownership-ip.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 4072
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement/
[children] =>
)
[ip-ownership.protection-results.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 4075
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-2/
[children] =>
)
[liability.indemnity.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 4081
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-8/
[children] =>
)
[liability.insurance.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 109
[slug] => insurance
[title] => Insurance
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Insurance
[provision_id] => 4082
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-9/
[children] =>
)
[liability.warranties.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 4085
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-11/
[children] =>
)
[term-and-termination.effect-of-termination.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 4086
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12/
[children] =>
)
[term-and-termination.term-of-agreement.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 4086
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12/
[children] =>
)
[term-and-termination.termination-and-withdrawal.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 4086
[provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12/
[children] =>
)
)
US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
2020
Government
Industry
Drug
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.ati-regeneron-covid-19-antibodies-manufacturing-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 3765
[provision_permalink] => https://ghiaa.org/provision_document/ati-regeneron-covid-19-antibodies-manufacturing-agreement-2/
[children] =>
)
[business-model.regulatory-strategy.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 2822
[provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4/
[children] =>
)
[business-model.royalties-and-payments.ati-regeneron-covid-19-antibodies-manufacturing-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3696
[provision_permalink] => https://ghiaa.org/provision_document/ati-regeneron-covid-19-antibodies-manufacturing-agreement/
[children] =>
)
[business-model.supply-purchase-of-products.ati-regeneron-covid-19-antibodies-manufacturing-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3696
[provision_permalink] => https://ghiaa.org/provision_document/ati-regeneron-covid-19-antibodies-manufacturing-agreement/
[children] =>
)
[information-sharing.information-sharing-information-sharing.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 2820
[provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2/
[children] =>
)
[ip-ownership.license-grants.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 2820
[provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2/
[children] =>
)
[ip-ownership.ownership-ip.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 2820
[provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2/
[children] =>
)
[ip-ownership.protection-results.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 2820
[provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2/
[children] =>
)
[liability.indemnity.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 2824
[provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6/
[children] =>
)
)
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Vaccine
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 3782
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3/
[children] =>
)
[access-to-medicines.pricing.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 100
[slug] => pricing
[title] => Affordable pricing
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Affordable pricing
[provision_id] => 3786
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7/
[children] =>
)
[business-model.regulatory-strategy.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 3781
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2/
[children] =>
)
[business-model.roles-responsibilities.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3792
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12/
[children] =>
)
[business-model.royalties-and-payments.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3786
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7/
[children] =>
)
[business-model.supply-purchase-of-products.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3786
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7/
[children] =>
)
[information-sharing.confidentiality.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3784
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5/
[children] =>
)
[information-sharing.information-sharing-information-sharing.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3778
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement/
[children] =>
)
[information-sharing.publication-of-results.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 3783
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4/
[children] =>
)
[ip-ownership.license-grants.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3778
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement/
[children] =>
)
[ip-ownership.ownership-ip.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3778
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement/
[children] =>
)
[ip-ownership.protection-results.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 3778
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement/
[children] =>
)
[liability.indemnity.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3789
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9/
[children] =>
)
[liability.warranties.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 3788
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8/
[children] =>
)
[term-and-termination.effect-of-termination.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 3791
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11/
[children] =>
)
[term-and-termination.term-of-agreement.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3791
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11/
[children] =>
)
[term-and-termination.termination-and-withdrawal.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 3791
[provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11/
[children] =>
)
)
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
[access-to-medicines.ensuring-continuity.moderna-dod-supply-agreement-for-mrna-vaccine-4] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 2452
[provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-4/
[children] =>
)
[business-model.regulatory-strategy.moderna-dod-supply-agreement-for-mrna-vaccine-2] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 2449
[provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-2/
[children] =>
)
[business-model.supply-purchase-of-products.dod-moderna-covid-19-vaccine-supply-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3495
[provision_permalink] => https://ghiaa.org/provision_document/dod-moderna-covid-19-vaccine-supply-agreement/
[children] =>
)
[information-sharing.confidentiality.moderna-dod-supply-agreement-for-mrna-vaccine] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 2448
[provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine/
[children] =>
)
[liability.indemnity.moderna-dod-supply-agreement-for-mrna-vaccine-3] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 2450
[provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-3/
[children] =>
)
)
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 2739
[provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6/
[children] =>
)
[business-model.regulatory-strategy.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 2737
[provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4/
[children] =>
)
[information-sharing.information-sharing-information-sharing.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 2736
[provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3/
[children] =>
)
[information-sharing.publication-of-results.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 2741
[provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7/
[children] =>
)
[ip-ownership.license-grants.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 2736
[provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3/
[children] =>
)
[ip-ownership.ownership-ip.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 2734
[provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine/
[children] =>
)
[liability.indemnity.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 2743
[provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9/
[children] =>
)
[liability.warranties.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8] => GHIAA2019\IssueItem Object
(
[ID] => 81
[slug] => warranties
[title] => Representations & Warranties
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Representations & Warranties
[provision_id] => 2742
[provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8/
[children] =>
)
[term-and-termination.effect-of-termination.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 2744
[provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12/
[children] =>
)
[term-and-termination.term-of-agreement.2748] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 2748
[provision_permalink] => https://ghiaa.org/provision_document/2748/
[children] =>
)
[term-and-termination.termination-and-withdrawal.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 2749
[provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11/
[children] =>
)
)
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
[access-to-medicines.ensuring-continuity.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 2466
[provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2/
[children] =>
)
[business-model.regulatory-strategy.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 2463
[provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5/
[children] =>
)
[business-model.roles-responsibilities.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 2467
[provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development/
[children] =>
)
[business-model.royalties-and-payments.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 2457
[provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10/
[children] =>
)
[information-sharing.confidentiality.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 2464
[provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4/
[children] =>
)
[information-sharing.publication-of-results.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 2461
[provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7/
[children] =>
)
[ip-ownership.license-grants.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 2462
[provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6/
[children] =>
)
[liability.indemnity.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 2465
[provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3/
[children] =>
)
)
US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
2020
Government
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
[access-to-medicines.ensuring-continuity.us-government-ology-bioservices-covid-19-plasmid-procurement-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 8447
[provision_permalink] => https://ghiaa.org/provision_document/us-government-ology-bioservices-covid-19-plasmid-procurement-agreement/
[children] =>
)
[access-to-medicines.outbreak-preparedness.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 102
[slug] => outbreak-preparedness
[title] => Preparedness & response
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Preparedness & response
[provision_id] => 3352
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement/
[children] =>
)
[business-model.regulatory-strategy.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 3366
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8/
[children] =>
)
[business-model.roles-responsibilities.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 3372
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12/
[children] =>
)
[business-model.royalties-and-payments.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 3354
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2/
[children] =>
)
[business-model.supply-purchase-of-products.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement] => GHIAA2019\IssueItem Object
(
[ID] => 268
[slug] => supply-purchase-of-products
[title] => Product supply
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Product supply
[provision_id] => 3352
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement/
[children] =>
)
[information-sharing.confidentiality.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Confidentiality
[provision_id] => 3364
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7/
[children] =>
)
[information-sharing.information-sharing-information-sharing.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 257
[slug] => information-sharing-information-sharing
[title] => Information sharing
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Information sharing
[provision_id] => 3360
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4/
[children] =>
)
[information-sharing.publication-of-results.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 290
[slug] => publication-of-results
[title] => Publication of Results
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Protecting & sharing information | Publication of Results
[provision_id] => 3368
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9/
[children] =>
)
[ip-ownership.license-grants.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 88
[slug] => license-grants
[title] => License Grants
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | License Grants
[provision_id] => 3360
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4/
[children] =>
)
[ip-ownership.ownership-ip.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 87
[slug] => ownership-ip
[title] => Ownership of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Ownership of IP
[provision_id] => 3360
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4/
[children] =>
)
[ip-ownership.protection-results.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5] => GHIAA2019\IssueItem Object
(
[ID] => 90
[slug] => protection-results
[title] => Protection of IP
[parent] => 48
[parent_slug] => ip-ownership
[parent_title] => Intellectual Property
[display_title] => Intellectual Property | Protection of IP
[provision_id] => 3361
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5/
[children] =>
)
[liability.indemnity.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10] => GHIAA2019\IssueItem Object
(
[ID] => 80
[slug] => indemnity
[title] => Indemnification & liability
[parent] => 50
[parent_slug] => liability
[parent_title] => Liability
[display_title] => Liability | Indemnification & liability
[provision_id] => 3370
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10/
[children] =>
)
[term-and-termination.effect-of-termination.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 72
[slug] => effect-of-termination
[title] => Effects of termination
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Effects of termination
[provision_id] => 3356
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3/
[children] =>
)
[term-and-termination.term-of-agreement.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 76
[slug] => term-of-agreement
[title] => Term of agreement
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Term of agreement
[provision_id] => 3356
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3/
[children] =>
)
[term-and-termination.termination-and-withdrawal.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 74
[slug] => termination-and-withdrawal
[title] => Termination & withdrawal
[parent] => 52
[parent_slug] => term-and-termination
[parent_title] => Term & termination
[display_title] => Term & termination | Termination & withdrawal
[provision_id] => 3356
[provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3/
[children] =>
)
)
Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
2010
Funder
Industry
Drug
Discovery/Concept
Preclinical
Array
(
[access-to-medicines.ensuring-continuity.wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-3] => GHIAA2019\IssueItem Object
(
[ID] => 281
[slug] => ensuring-continuity
[title] => Ensuring continuity
[parent] => 46
[parent_slug] => access-to-medicines
[parent_title] => Equitable Access
[display_title] => Equitable Access | Ensuring continuity
[provision_id] => 6277
[provision_permalink] => https://ghiaa.org/provision_document/wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-3/
[children] =>
)
[business-model.regulatory-strategy.wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-9] => GHIAA2019\IssueItem Object
(
[ID] => 56
[slug] => regulatory-strategy
[title] => Regulatory strategy
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Regulatory strategy
[provision_id] => 6284
[provision_permalink] => https://ghiaa.org/provision_document/wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-9/
[children] =>
)
[business-model.roles-responsibilities.wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-8] => GHIAA2019\IssueItem Object
(
[ID] => 278
[slug] => roles-responsibilities
[title] => Governance
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Governance
[provision_id] => 6283
[provision_permalink] => https://ghiaa.org/provision_document/wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-8/
[children] =>
)
[business-model.royalties-and-payments.wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-7] => GHIAA2019\IssueItem Object
(
[ID] => 70
[slug] => royalties-and-payments
[title] => Payment Structures
[parent] => 53
[parent_slug] => business-model
[parent_title] => Business model
[display_title] => Business model | Payment Structures
[provision_id] => 6282
[provision_permalink] => https://ghiaa.org/provision_document/wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-7/
[children] =>
)
[information-sharing.confidentiality.wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-4] => GHIAA2019\IssueItem Object
(
[ID] => 84
[slug] => confidentiality
[title] => Confidentiality
[parent] => 49
[parent_slug] => information-sharing
[parent_title] => Protecting & sharing information
[display_title] => Prote 